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ABSTRACf 
Purpose: To determine whether the short-term use of inhaled beclomethasone 
significantly decreases the duration of paroxysmal coughing in young children with early 
pertussis, as compared with inhaled placebo. 
Design: Randomized, double-blintL placebo-controlled clinical trial. 
Subjects: Subjects were recruited from the outpatient department and microbiology 
laboratory of the Janeway Child Health Centre. General practitioners and public health 
nurses in the area were also canvassed for referrals of potential subjects with clinical 
pertussis. From a total of210 contacted subjects who met the case definition, 23 were 
enrolled with 18 staying in the study long enough to provide usable data. 
Method: Subjects were randomly allocated to receive inhaled beclomethasone or 
placebo three times daily for 30 days. Cough counts were recorded daily by parents and 
teachers. The time to cessation of coughing for both groups was considered the primary 
outcome variable. 
Numerous methodological problems were encountered in the design and 
implementation of this trial. These included difficulties in choosing a primary outcome 
variable and a corresponding measurement instnunent, problems in the assumptions made 
in the determination of sample size, difficulties with case definitions, and problems with 
recruitment and retention of subjects. These problems are reviewed in detail and 
solutions which may be applied to future trials are proposed. 
11 
Results: Subjects ranged in age from 2 to 95 months. The mean duration of coughing at 
entry into the study was 14 days. The mean duration of coughing following entry into the 
study was 26.8 days in the beclomethasone group and 21.4 days in the placebo group (p = 
0.2 ). 
Conclusions: Significant problems were encountered with the recruitment for this study 
leading to low numbers of subjects being enrolled and a subsequent low power. Such 
problems have precluded any definite conclusions. However, data suggest that the use of 
inhaled beclomethasone is not effective in the treatment of patients with pertussis 
infection and may actually prolong the duration of coughing. Further trials are needed if 
this question is to be answered. Suggestions for the design and implementation of such a 
trial, or a trial of other therapies for pertussis, are provided and discussed. 
lll 
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CHAPTER I 
Introduction and Background 
Introduction 
Pertussis or ''whooping cough" was ftrst described in 1578 by a French 
physician in Paris, France, following an epidemic in that city during the same yeazl. 
Today, pertussis continues to be a significant cause of childhood morbidity around the 
world 2.s. The disease is caused by the bacterium Borde tel/a pertussis. a small, non-
motile, fastidious, gram negative, rod-shaped bacterium which infects humans 
exclusively. Transmission results from contact with airborne droplets or particles from 
the respiratory tract of an infected individual. While attack rates vary with immunization 
status6• it has been reported that from 90-l 00% of susceptible individuals in a household 
will develop symptoms of pertussis when exposed to an infected household mernber 2 . 
Clinical Manifestations of Pertussis 
Clinically, the disease is characterized by three stages which together last 
an average of 6 to 8 weeks. After a mean incubation period of seven days the catarrhal 
stage begins. During this stage the patient experiences mainly upper respiratory tract 
infection symptoms including lacrimation, rhinorrhea, mild cough, conjunctival injection 
and a low-grade fever. This period usually lasts from 1 to 2 weeks and is followed by the 
much more bothersome paroxysmal stage. The paroxysmal stage is characterized by 
increasingly frequent and severe coughs, which often occur in repetitive series. The 
coughing paroxysms. as they are kno~ may or may not be followed by a sudden 
massive inspiratory effort. When present. this creates the characteristic "whooping" 
sound as air rushes by a narrowed glottis. lt is from this sound that the disease takes its 
name. Coughing paroxysms may be accompanied by cyanosis. bulging eyes, salivation, 
lacrimation or other symptoms, and often occur sequentially, in rapid succession. 
Coughing episodes are frequently followed by vomiting. The paroxysmal phase usually 
lasts for 2 to 4 weeks and is the most severe and dangerous part of the illness 1• Children 
are often exhausted during this period, and may lose weight to the point of requiring 
parenteral nutrition due to the incessant vomiting 7·1 • Occasionally, the disease may be 
complicated with apneas and pneumonia 1• 1 . Prolonged coughing may result in tissue 
hypoxia with subsequent hypoxic damage 1, or even death 9• 
The fmal stage of the illness is known as the convalescent stage and is 
marked by a decrease in the frequency and severity of episodes of coughing, whooping 
and vomiting. While this phase usually lasts for I to 2 weeks, coughing can persist for 
months, and some patients complain of persistent symptoms associated with upper 
respiratory infections for years afterwards 1• 
2 
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Epidemiology of Pertussis 
While the North American incidence of pertussis infection has decreased 
significantly since the advent of universal vaccination. both endemic and epidemic 
pertussis infection continues to occur. Recent years have witnessed a resurgence of the 
disease even in the immunized population 2•10• 11 • Between 1992 and 1993, 23 deaths were 
reported as a result of pertussis infection in the United States 9 • 
Canada is affected to an even greater degree than the United States (US) 
with an estimated annual incidence of 1 0 cases per l 00 000 children reported during the 
1970's - 1980's 1 . This rate had climbed to 12 cases per 1 00 000 for the period between 
1984 and 1993 12 , with a high of almost 3 5 cases per l 00 000 reported in 1994 D . This 
compares with a rate of 0.83-1.2 cases per l 00 000 in the US 12 • While more recent 
estimates of disease incidence among children are not available, overall Canadian and 
Newfoundland incidence rates are provided as Table l.lu. 
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Table 1.1 -The Incidence of Pertussis in Canada and Newfoundland ( 1990-1995) 13 
CANADA NEWFOUNDLAND 
YEAR NUMBER RATE /100 000 NUMBER RATE /100 000 
1990 8030 30.2 ll 1.9 
1991 2724 10.1 27 4.7 
1992 3605 13.2 44 7.6 
1993 7396 25.7 39 6.7 
1994 10 151 34.7 334 57.3 
1995 - . 96* 16.9* 
•preliminary figures only 14 • 
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Though Newfoundland appears to have an annual incidence significantly 
below the national average in all but the final year of complete reporting, it is possible 
that this represents significant under-reporting. ln addition to the culture-positive patients 
reported in the table, there may be others that are diagnosed clinically by general 
practitioners or other health professionals working in the community. These patients may 
never be cultured, thereby excluding their data from the statistics. Such a phenomenon 
was observed with an enhanced reporting program in Nova Scotia 10 • This study 
documented a nine-fold increase in pertussis infection when enhanced surveillance was 
undertaken. Hence, the burden of disease may be significantly greater than it appears. 
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Prevention of Pertussis 
Most of the recent research work in pertussis has focused on prevention 
through vaccination. From the time that Jenner first gave an injection of cowpox to his 
one-year-old son in an effort to prevent the more serious smallpox infection 15 , the 
medical establishment has sought ways to prevent infectious ailments through the use of 
vaccines. Today, smallpox has been eradicated as a result. and measles has been targeted 
for the same fate in the next century 16 • While the eradication of pertussis is also a 
worthwhile goal, such a prospect remains a distant hope with current vaccines. In 1993 
pertussis became the '4 most prevalent vaccine-preventable disease among US children 
younger than 5 years" and was the cause of 23 reported deaths in that country between 
1992 and 1993 9 • [n Canada. similar fmdings have been reported with outbreaks 
occurring in the Yukon. Quebec, and Nova Scotia 10• 17•19 • 
Whole Cell Pertussis Vaccines 
Currently employed pertussis vaccines are known as whole cell vaccines 
because they are manufactured from the whole Bordetella pertussis organism. Under 
current whole cell vaccine manufacturing practices, the organisms are grown in bulk 
culture and then harvested. After centrifugation to concentrate them, the organisms, are 
suspended in a buffered saline solution. The bacteria are then killed or partially 
detoxified by physical or chemical methods producing a mixture of multiple bacterial 
antigens. This mixture is then combined with diphtheria and tetanus toxoids adsorbed to 
aluminum to produce the widely used "DTP"(d.iphtheria., tetanus. pertussis) vaccine 20 • 
Efficacy and Effectiveness of Current Vaccines 
7 
The persistence of clinical pertussis infection relates to problems with 
vaccine efficacy and vaccine effectiveness. These problems have been detailed by several 
investigators in the recent past 2. 11• 21 • 22• While the terms are often used interchangeably in 
the literature, vaccine effectiveness refers to "the ability of an intervention to produce the 
desired beneficial effect in actual use." u . Consequently, any factors which decrease use 
of the vaccine. in addition to problems intrinsic to the vaccine itself, will necessarily have 
an impact on effectiveness. In contrast. efficacy refers to "the ability of an intervention to 
produce the desired beneficial effect in expert hands and under ideal circumstances." 2~ 
Efficacy, therefore, is primarily dependent on the inherent properties of the vaccine itself. 
Efficacy of the whole cell vaccines currently in use in Canada and the 
United States is difficult to estimate due to the absence of a gold standard for diagnosis. 
Efficacy rates are, therefore, dependent on the case definition used to determine infection 
in the population at risk. This problem is further compounded by the fact that vaccines 
currently in use were not tested in clinical trials prior to their introduction 21 • Rather, they 
were compared to former vaccines tested in a large randomized controlled trial conducted 
in the United Kingdom following World War II 25 • The unit of comparison was the 
"mouse protection test," 26 a test to determine the in vitro potency of a particuJar vaccine 
preparation. The UK trial had shown a positive correlation between the results of the 
mouse potency test and the clinical efficacy of pertussis vaccines in immunized children. 
Consequently, the results of this test on the new vaccines were accepted as adequate for 
licensure 21 • 
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Subsequent post-marketing studies of the current whole-cell vaccines, 
while sometimes reported to reflect efficacy, have more accurately estimated 
effectiveness by looking at the incidence of pertussis in defined populations of partially 
and completely immunized individuals. The interpretation and comparison of such 
studies is complicated by differences in vaccine schedules between different countries 27• 28 
, differences in vaccine components (eg. the addition of inactivated polio virus vaccines 
used in some Canadian provinces) 29, and differences in the settings in which the studies 
are conducted (communities. homes, schools and child-care centres) 6• 12. 21 • The practical 
result of these limitations is that the efficacy and effectiveness of whole cell pertussis 
vaccines currently in use are largely unknown. 
Attempts have been made to estimate effectiveness in the immunized 
populations in several countries, as alluded to above. In Canada, a study by Halperin et 
al10 examining the results of enhanced surveillance on the incidence of pertussis in the 
Nova Scotia population showed an effectiveness of 45% for the Connaught Laboratories 
quadrivalent vaccine (DPTP). This study defined pertussis as a positive nasopharyngeal 
9 
aspirate culture for pertussis or the presence of a cough for more than l week with two or 
more of the following: paroxysms~ cyanosis, vomiting or apnea. A subsequent study of 
Quebec children by De Serres' group 19 showed that in children who had received at least 
4 doses of vaccine, vaccine effectiveness was 61% with a 95% confidence interval of 44-
72% in child care centres and 60% with a 95% confidence interval of 1 0-82% in schools. 
Pertussis was defmed in this investigation as consisting of cough for at least 2 weeks with 
one or more "pertussis symptoms," namely paroxysmal coughing, post-tussive vomiting, 
apnea or whoop. When results were analysed using a case definition reflecting more 
severe disease (cough for 5 or more weeks), vaccine effectiveness improved to 71% for 
child care centres and 86% for schools. More recently, Bentsi-Enchill et a112 reported a 
similar result with their estimate of the effectiveness of the Connaught quadrivalent 
vaccine using cases from an outbreak of pertussis observed in the Nova Scotia population 
during 1994. They found that for fully immunized (five doses) children. the effectiveness 
was 57% (95% confidence interval: 23-77%) when a laboratory-based definition of 
pertussis infection was used (culture-positive nasopharyngeal aspirate). 
In the United States. data are more limited. In the largest prospective study 
there to date, Onorato et aJ 6 examined secondary attack rates in 34 7 pediatric family 
contacts of index cases with whooping cough. Her group investigated 1797 households 
for suspected pertussis cases. Of these, 945 households had a family member who met 
serological, culture or case definition requirements for entry into the study. By following 
10 
the I - 4 year old household contacts of these patients clinically, as well as with serial 
nasopharyngeal culture and acute and convalescent serology, the authors demonstrated a 
vaccine effectiveness (they call it efficacy) of95% for severe illness (cough for 35 or 
more days with paroxysms) and 64% for mild illness (any illness with cough). 
Reasons for this relative lack of effectiveness are speculative. Some 
authors suggest a decrease in efficacy of the vaccines currently in use 19• 30· 31 • lbis may 
be due to an as yet unknown mutation of the bacteria which renders it less easily affected 
than before. Others suggest the vaccine failure-induced accrual of susceptible individuals 
over time, resulting in an increase of vulnerable persons to a level above the threshold 
required for sustained transmission 21 • Several authors suggest waning vaccine protection 
over time so that adolescents and adults who were vaccinated in infancy can act as 
reservoirs for infection of younger children!. 22• 31 • It is believed by some that vaccine 
protection lasts a maximum of 12 years 2 • One group proposed that over reporting of 
vaccination by parents may be at least partially responsible for the apparent failure rates 6 • 
This group suggested that parents, aware of the need to vaccinate their children, may be 
hesitant to report the lack of vaccination to doctors and health department officials. This 
would lead to an increased pool of seemingly vaccinated but truly Wtvaccinated children 
being included in the calculations of vaccine efficacy and a resultant Wtderestirnation of 
that quantity. Finally, most authors believe that an increased awareness by physicians of 
the disease and its consequences has lead to increases in diagnosis 21• 2·1• 30 • 
ll 
Whole Cell Vaccine Side Effects 
As a further impediment to pertussis vaccine effectiveness, there has long 
been widespread public and professional dissatisfaction with its side effects profile 32 • 
Currently employed whole-cell pertussis vaccines are manufactured from Bordetella 
pertussis which are grown in bulk culture and then harvested. After centrifugation to 
concentrate the organisms, they are suspended in a buffered saline solution. The bacteria 
are then killed or partially detoxified by physical or chemical methods producing a 
mixture of multiple bacterial antigens. This mixture is then combined with diphtheria and 
tetanus toxoids adsorbed to aluminwn to produce the widely used 'DTP"(diphtheria, 
tetanus, pertussis) vaccine 21 • The whole cell vaccine thus contains many different 
pertussis antigens. Some of these antigens are immunogenic, while others have toxic 
effects 22 • It is these toxic antigens which are believed responsible for the side effects of 
pertussis immunization. 
Most of the side effects of whole cell pertussis vaccines are mild and 
associated with only local symptoms. The most common of these include local pain, 
redness, swelling and induration. Mild systemic reactions are also seen frequently and 
include low grade fevers, drowsiness, fretfulness, anorexia, and~ less commonly, 
vomitingl3• Very occasionally, more severe .. reactions" can occur. It is these reactions 
which have generated the most negative publicity and consequently, have been the most 
damaging. Such reactions include persistent, inconsolable crying (more than 3-4 hours), 
h.igh fever (~40.5oC), hypotonic-hyporesponsive episodes, convulsions, and 
encephalopathy 33 • Some authors have even suggested a link between sudden infant 
death syndrome (SIDS) and pertussis vaccine 34 , though such a link has not been 
supported in other studies 35• 36• 
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Negative publicity about such links and "reactions" in some countries has 
resulted, at least briefly, in the state-advised cessation of pertussis immtmization 2• 21 • 
This resulted in a loss of effectiveness for the vaccine in those countries and a subsequent 
surge in the incidence rate of pertussis infection 2• 37• In North America, while we have 
continued to use the whole cell vaccine since its introduction approximately 50 years 
ago21 • 30 , its use has met with increasing opposition. This is compoW1ded by the mass 
media which continues to promulgate the existence of severe and substantial side effects 
with ongoing fervourJO. 
However, despite the relatively extreme international response, even the 
existence of severe neurological reactions to pertussis vaccine continues to be 
controversial. The earliest reports of such reactions appeared in 1933 31 and have been 
continuously propagated since. The largest study of such reactions to date has been the 
National Childhood Encephalopathy Study (NCES) which was conducted in the UK in 
1976. It found that children admitted to hospital with a serious acute neurological illness 
were more likely than control children to have received DTP injection in the previous 7 
days than non-affected controls 39-4 1• Subsequent follow-up of these children has shown 
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that they continue to have chronic nervous system dysfunction 10 years later42 • 
Explanations for these effects have been varied but, in addition to a causal relationship, 
include the possibility that the DTP injection ·~ggered an acute neurological illness in 
children with underlying brain or metabolic abnonnalities. "33 It is felt that such children 
might go on to have chronic central nervous system dysfunction if exposed to other 
stressful stimuli such as fever or infection 33• The vaccine may also have caused an acute 
neurological illness in children for whom a chronic neurological disorder was destined to 
develop, whether or not the acute illness had developed 33 • The NCES data was not able to 
reliably discriminate between these possibilities. 
In contrast to the NCES da~ some studies have not found an increased 
risk of neurological complications related to DTP imrnunizationn47. In the largest North 
American investigation of this issue to date, Gale and his colleagues conducted a case-
control study in Washington and Oregon 41 • His group found that there was no 
statistically significant increase in risk of complex febrile seizures, seizures without fever, 
or acute encephalopathy I encephalitis in children who had received DTP vaccine within 7 
days of the onset of their illness. However, they acknowledged that their study had 
insufficient power to detect a difference in very rare events. 
The medical controversy surrounding such severe reactions, accompanied 
by ongoing public pressure, spurred governments and pharmaceutical companies to work 
to develop a less reactogenic vaccine for pertussis. It is through this process that the 
acellular pertussis vaccine was created 31 • Studies on the efficacy and reactogenicity of 
l.hese vaccines have dominated the pediatric literature on pertussis for the last ten years. 
Acellular Pertussis Vaccines 
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Acellular pertussis vaccines, rather than being mixtures of numerous 
pertussis antigens in unknown quantities and proportions, are composed of a number of 
purified, known pertussis antigens in a predetermined mixture. The actual antigens 
comprising the mixture vary with the brand of vaccine. All vaccines contain a chemically 
or biologically detoxified version of pertussis toxin (Pl), a protein elaborated by 
Bordetella pertussis"''. PT is believed by some 50• 51 to be the primary mediator of the 
clinical disease resulting from pertussis infection. Other investigators do not support this 
view "'1 . 
Other vaccine components include filamentous hemagglutinin. pertactin 
and fimbriae. These molecules are also proteins and are termed adhesins, reflecting their 
role in the adherence of B. pertussis to a variety of cells. It is thought that these adhesins 
are instrumental in the attachment of B pertussis to the respiratory epithelium. from where 
the organisms multiply and exert their clinical effects .aa . Paradoxically, they may also be 
involved in attaching the bacteria to macrophages 52 • Hence, the inclusion of such 
proteins in a vaccine could potentially prevent "the establishment of infection or make 
organisms more susceptible to host defences" ... . 
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Acellular pertussis vaccines were first tested in Japan where they displayed 
effectiveness rates similar to, but slightly lower than those observed with whole cell 
pertussis preparations '3 • The side effects profile, however, was much improved over that 
seen with the latters... Similar findings have been observed with studies completed in 
Europe and North America over the last decade 3 u2.ss,.S6. While insufficient numbers of 
subjects have been tested to ascertain the incidence of rare clinical events such as 
encephalopathy or SIDS and their potential relationship to the new vaccines, minor and 
moderate side effects have been significantly reduced. The improvement in the latter has 
been so great that the American Academy of Pediatrics Committee on Immunization has 
recently changed its recommendations so that acellular pertussis preparations are now the 
pertussis vaccine of choice for infants and children in the United States 56 • Canada is 
expected to adopt similar recommendations soon. The interested reader is referred to 
Cherry' s excellent, comprehensive review of this topic for a more detailed discussion of 
the history of acellular pertussis vaccines, and the comparative efficacy and reactogenicity 
results of all of the individual trials to date s.. . 
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Implications of Acellular Pertussis Vaccines for the Future 
Despite these promising improvements in side effects profiles, it is notable 
that none of the trials of acellular pertussis vaccine showed an improvement in clinical 
efficacy when compared with the standard whole cell pertus.sis vaccine as currently 
administered in North America (total of 5 doses) S6. This means that breakthrough cases 
continue to be likely and that if eradication is ever to be achieved~ a repeat booster dose of 
vaccine may be required in adolescence or adulthood 2 • It also indicates that while 
prevention may be optimal~ in the absence of a perfect vaccine, and in the face of the 
evidence above. the practical necessity of providing some effective treatment for the 
disease remains present. 
Treatment of Pertussis 
Historical Treatments 
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The need for an effective treatment for established pertussis illness is not 
new. As early as the sixteenth century, the chin cough, as it was known, was creating 
treatment problems for the "physicians" of the day. At that time. Gerard, a well-known 
herbali~ recommended the plant lysimachia (Creeping Jenny) which "boiled in wine with 
a little honie, or meade, prevaileth much against the cough in children called the chinne 
cough." s7 • The less conventional, tried even more drastic measures to get rid of 
whooping cough. A tribe in India uses a broth made of the flesh of the bird Acridotherus 
tristis to cure patients of paroxysms. Rathore and Swarup sa report that patients taking 
such a concoction could fmd some relief from coughing within 24 hours of its use and 
could be rid of the disease within one week. The following passage is extracted from an 
article by Yates printed in Nursing Mirror in 1978 detailing some more of these folk cures 
for whooping cough: 
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"Many a whooping child was required to wear around the neck one 
of his godmother's garters or a lace from ber stays. A cure could be 
effected~ too, by canying the patient. fasting, into three different 
parishes on a Sunday moming ...... the sufferer might be given new 
milk from a cup made of holly wood, or wear a necklace made of 
short threaded twigs from an elder grown in a churchyard ...... A 
bramble growing in the ground at both ends was specially prized -
the whooping child was passed under and over it nine times on 
three successive mornings before sunrise, while those present 
repeated "under the briar and over the briar, I wish to leave the 
chin-cough here." ...... .It was customary .... in parts of northern 
England, to take a bowl of milk, get a ferret to drink half of it and 
then give the remainder to the patient ....... A favourite gipsy remedy 
was to let a black snail crawl over a saucer of brown sugar and 
make it slimy. The sugar was then fed to the patient. A muslin bag 
filled with live spiders and worn night and day around the neck was 
equally effective. '' 
More modem physicians have also tried multiple remedies, both 
conventional and unconventional, to treat afflicted children. Unfortunately though, the 
development of an effective treatment for the paroxysmal coughing of pertussis patients 
has been hindered by the lack of a complete understanding of the pathophysiology behind 
its development. The following sections will review these remedies and the proposed 
pathophysiological mechanisms behind them in detaiL 
Antibiotics 
Many pathophysiological mechanisms for the cough have been proposed, 
but to date, none have been clearly proven to be responsible. Perhaps the most logical 
would seem to be that the infection was directly responsible. Treating the infection with 
an effective antibiotic would then presumably eradicate the organism and result in the 
disappearance of symptoms. Yet, clinical observation shows that this is only part of the 
answer. A review by Broomhall and Herxheimer s9 points out that as early as 1953, the 
Medical Research Council trial 60 showed that chloramphenicol and chlortetracycline 
could shorten the course of the illness and clear the nasopharynx of disease if given 
during the catarrhal phase of the illness, but had little effect on symptoms if given later 
on. Subsequent investigations have since shown similar results for erythromycin and 
cotrimoxazole 61 • While on the surface this sounds promising, since the disease is often 
recognized later in the course, after the paroxysmal phase bas started 1, treatment in the 
catarrhal phase is somewhat impractical. Additionally, the child must still endure a full 
month of coughing. 
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The erythromycin results have recently been supported by several 
Canadian trials. The fJISt showed that among immunized patients, those treated with 
erythromycin in the catarrhal phase of their disease had shorter median durations of cough 
(38 as compared with 57 days) and paroxysms (28 as compared with 44 days) 62 • The 
second showed that seven days of treatment with erythromycin estolate was as effective 
for nasopharyngeal eradication of Bordetella Pertussis as the standard fourteen day 
treatment, but the duration of clinical symptoms was not significantly different between 
the two groups 63 • Hence, antibiotics are clearly not the only answer. 
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Immune Globulin 
ln the same way that antibiotics might be expected to work to eradicate 
coughing, some investigators support the use of immune globulin to treat patients with 
pertussis. Widely purported to be of great value in the 1930's and 1940's, it subsequently 
fell out of favour in the 1950's and 60's when repeat studies failed to conftrm the initial 
positive effects 64 • Despite the opinions held on both sides, however, the initial evidence 
to support or refute the use of gamma globulin was not based on well-designed clinical 
trials 65 • The ftrst randomised, double-blind, placebo-controlled clinical trial was 
completed in 1971 6s and showed no significant group differences in the number of 
coughs, whoops, vomiting episodes or suctioning required in hospitalized patients with 
pertussis. A second randomized controlled trial using a higher dose of pertussis 
hyperimmune globulin was performed in 1991 64 • This study showed a significant 
decrease in the number of whoops for the treatment group, but no difference in the 
number of coughing paroxysms or vomiting episodes. The study also allowed what it 
called "standard" treatment of pertussis with such medications as erythromycin and 
salbutamol. This leaves it open to criticism due to the possibility of group contamination 
from the other treatments. Hence, gamma globulin does not appear to be effective for 
cough reduction. 
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Sedative-Hypnotics 
Some investigators felt the cough was central in origin, since it seems to 
persist long after the "active disease" has gone from the respiratory tract. They 
consequently advocate sedatives such as phenobarbital and diazepam 66 • There have been 
no clinical trials on this issue to date. Evidence is completely anecdotal, consisting 
mainly of letters to the editor of various clinical journals describing individual cases or 
small groups of patients who responded to such treatment 59• While sedation may be 
effective for symptom control. it is unclear as to whether this represents an effect on the 
underlying pathophysiological mechanism or is simply a result of the sedation. 
Additionally, the side effects of these medications are not insignificant Most modem 
physicians would agree that risks versus benefits must be carefully weighed before 
embarking on such a course of treatment. For this reason, sedative-hypnotics to treat 
whooping cough have largely fallen out of favour. 
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P2 Agonists 
Another potential explanation for the incessant coughing is bronchial 
hyper-responsiveness following pertussis infection. This stems from animal work in the 
1950's which showed that certain strains of mice or rats became hypersensitive to 
nonspecific stimuli following B. pertussis infection 67 • Further support for this theory 
was claimed by Badr-EI-Din and his colleagues who noted an attenuated hyperglycemic 
response to epinephrine in pertussis patients 68• These researchers postulated that the 
mechanism for such airway hyper-responsiveness and pancreatic hyporesponsiveness may 
have been beta receptor blockade and, therefore, that beta agonists would be a logical 
treatment. Given current understanding of the pathophysiology of pertussis infectior4 it 
seems more likely that the pancreatic hyporesponsiveness to epinephrine was the result of 
high circulating levels of pertussis toxin. leading to hyperinsulinism in research subjects2 • 
The high levels of this counter-regulatory hormone might cause an attenuated 
hyperglycemic response to epinephrine. 
A single clinical trial of salbutamol, a beta receptor agonist, in Egyptian 
children suggested a potential beneficial effect with an 80% decrease in the number of 
coughing paroxysms in children treated with nebulized salbutamol 69• However~ design 
and implementation flaws in this paper make interpretation of the results difficult. 
Subsequent investigations using oral salbutamol, though also limited in their designs, 
have had conflicting fmdings. Two studies found no difference in the number or duration 
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of paroxysmal coughing spells reported by pertussis patients 70• 71 , though one of these did 
report that the nwnber of whoops was decreased in the group treated with salbutamol 70 • 
One study of 50 patients. which was reported in the fonn of a letter to the Lancet. did fmd 
a difference in the number and duration of both cough paroxysms and whooping between 
the treated and untreated group n. Unfortunately, the authors did not provide any 
statistical analysis for the data so the significance of the result is unknown. Consequently. 
the question of the utility of salbutamol in pertussis has still not been effectively 
answered, though current concepts of pathogenesis do not support a bronchospastic origin 
for respiratory symptoms. 
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Other Treatments 
Other researchers have proposed less conventional treatments. Flights at 
high altitude have apparently been advocated by some physicians for many years n .?s . A 
recent letter to the editor of the Lancet detailed one physician-pilot's experience with 
several patients who reportedly had transient relief from this "treatment" 73 • 
Unfortwlately, the cough did return when the plane landed. Another pediatrician reports 
using repeated subcutaneous injections of"woop," a pure pertussis vaccine on a weekly 
basis for four weeks or until coughing stoppe<L whichever came first 76 • He reports better 
results in the partially immunized population. saying that occasionally after just a single 
injection, the child stops coughing. No figures detailing overall results are provided. The 
pathophysiological basis for these treatments remains to be elucidated. 
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Steroids 
Of all of the treatments proposed for pertussis, however, perhaps that 
which has spurred the most discussion has been the use of corticosteroids. 
Pathophysiologically, the use of steroids is supponed by presently held theories 
concerning infection and the generation of symptoms. One of these theories has recently 
been described by Hewlett. The process is believed to begin with the inhalation of 
Bordetella pertussis-containing droplets, aerosolized by the coughing of an affected 
individual, by a susceptible host. These organisms then attach to the ciliated cells in the 
nasopharyn..x by means of various surface proteins known as adhesins. Anchored by these 
adhesins, the organisms proliferate and spread. eventually extending down to attach to the 
epithelial cells of the trachea and bronchi. Once established in the tracheobronchial tree, 
the bacteria are believed to produce a number of cytotoxins including pertussis toxin (PT) 
and the more recently described tracheal cytotoxin (TCT). These toxins result in paralysis 
of cilia and the destruction of the tracheobronchial cells. With increasing damage, the 
host's immune system is activated and inflammatory cells flood the area"'1 . The 
combination of sloughed cells and inflammatory exudate may explain the incessant 
coughing seen in the disease during the paroxysmal phase. These findings are supported 
by the fact that microscopic examination of the respiratocy tracts of patients with early 
pertussis shows inflammation of the mucosal lining 1 • Further examination shows the 
infiltrate to be primarily lymphocytes and polymorphonuclear leukocytes 77 • In the same 
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way that steroids work to decrease the airway inflammation in conditions such as asthma, 
through their alteration of lymphocyte DNA synthesis 71 , they could be expected to work 
in pertussis. 
An alternate hypothesis has been proposed by researchers in Japan who 
have recently documented an increase in substance P, a neuropeptide known to cause 
coughs in guinea pigs, in patients with pertussis. The elevation in the peptide level 
resolves with recovery from the paroxysmal phase of the illness 'N. Substance Pis 
elaborated by the sensory nerve tenninals ofC-fibres found in the airways. While 
normally protected by the respiratory epithelium~ the authors propose that exfoliation of 
the bronchial epithelial cells during perrussis infection exposes the unmyelinated C-fibres 
making them more sensitive to stimulation by irritants and increasing production of 
substance P. If this is the case. then perhaps decreasing airway inflammation with the use 
of anti-inflammatory medications such as corticosteroids could reduce this exfoliation, 
thereby reducing substance P and the coughing observed. 
Unfortunately, all of the steroid studies have been marked by significant 
methodological errors, as discussed in the literature review to follow. Additionally, most 
studies to date have focused on the use of systemic steroids as opposed to the inhaled 
agents. Considerable unpublished anecdotal evidence exists to support the use of the 
newer inhaled steroids in this population. For example, a number of staff pediatricians at 
the Janeway Child Health Centre have found favourable responses in patients treated with 
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inhaled steroids when compared with patients who are not. More recently a letter to the 
editor of The Pediatric Infectious Diseases Journal reported on the treatment of 27 
pediatric patients with inhaled budesonide 10 • All improved, based on a clinical scoring 
system~ within 72 hours of beginning treatment. This is the first published account of the 
use of inhaled steroids in pertussis. There were numerous problems with the design of 
this study. These included the lack of specified inclusion/exclusion criteria. the non-
randomized treatment administration~ and the absence of a specified outcome measure. 
among others. When combined with the lack of detailed reporting of this study. such 
problems make it useful only for hypothesis-generation. 
Consequently, the magnitude of the steroid effect clearly needed formal 
assessment before the question of usefulness could be adequately answered. For this 
reason. a study was proposed to examine the effectiveness of inhaled steroids in reducing 
the duration of paroxysmal coughing in patients with pertussis seen at the Janeway Child 
Health Centre. 
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Review of the Litentture on Steroid Use in Pertussis 
lnterest in using steroids to treat pertussis began in 1973 with a study by 
Zoumboulak.is. Anagnostakis, AJbanis and Matsaniotis 11 . These researchers found a 
decrease in the number of coughing paroxysms and vomiting episodes, as well as a more 
rapid recovery, in pertussis patients who were treated with intramuscular hydrocortisone, 
as compared with untreated controls. Subsequently, there have been only seven other 
reports which hav~ examined the use of steroids in this disease 69• 71•10•12"15• These have 
shown variable results when other steroid medications have been tested. Five studies and 
a case report upheld the original beneficial effect on coughing 7u 1·12•14, while two other 
trials were unable to document any significant differences between steroid and control 
groups. The Badr-El-Din et al. study 69 , however, did find a reduction in vomiting and an 
improvement in general well-being in the steroid-treated group. Also, both the Roberts et 
al. study 15 and the Badr-El-Din et al. study 69 showed a reduction in the duration of 
paroxysmal coughing in the steroid group, but were unable to show statistical 
significance. 
Unfortunately, however, all of these studies were strewn with flaws. First, 
most of them had an extremely small sample size 69•71·~~-'·•s. Four of them had 1 0 or fewer 
patients per study arm 69•7uus. Hence, findings have to be reviewed in that light. 
Secondly, many had problems with outcome variables. None of the studies clearly 
defined the primary outcome variable under investigation. While most used the frequency 
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of paroxysmal coughing episodes as an outcome 69•11·12, none defined what a paroxysm 
was. Some studies used multiple outcome variables without designating one as the 
primary variable. making analysis and interpretation difficult ao.a:z..a5 • As well. methods of 
data collection were not given in the majority of papers 69•78·80·nu.u . Invalid or unreliable 
instrwnents are another source of potential bias in the existing research. 
Thirdly, there were problems related to subject selection and inclusion in 
the studies. Most researchers used a combination of clinical and laboratory data to 
diagnose pertussis for the purposes of the study 69•7u 2• However, none clearly defmed 
what specific laboratory data were used in the diagnostic decision and only one pape~ 
listed the specific clinical inclusion criteria used. Additionally, the majority of 
investigators did not use any particular duration of coughing at entry into the study as an 
inclusion criterion 69•71•10•1s. This leads to possible bias through the assignment of patients 
with later disease to a particular group, since these patients might have been expected to 
improve more rapidly than those with early disease. 
Also of consideration were the problems in subject randomization. While 
three of the trials claimed to be randomized 7ut.as, only one gave the procedure used in the 
"randomization" process11 , namely, assigning subjects alternately to treatment and control 
groups. This does not constitute true randomization and must be considered a flaw in the 
study. 
Perhaps the greatest difficulties in interpretation of the above studies are 
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encountered in the area of data analysis. The most notable problem in this regard is that 
researchers failed to give the statistical test used in the analysis of the data 69·71·11.as. This 
makes interpretation of their work virtually impossible. One study concluded 
significance without apparently analysing the datan. As well, no study provided data to 
substantiate the asswnptions made that the outcome variables measured had a normal 
distribution. This also limits the usefulness of the data. 
Finally, it is also significant to note that no researcher was able to 
docwnent any ill effects resulting from the use of systemic steroids in patients with 
pertussis. One group specifically examined this issue as it relates to lymphocyte 
subpopulations and the possibility of significant immune suppression 11• They found a 
decrease in the cytotoxic/suppressor T -cells in the steroid-treated group which was 
associated with a significant improvement in whooping and no clinical ill-effects when 
compared with untreated controls. 
CHAPTER2 
Research Question and Method 
Research Question 
Does the short-tenn use of inhaled beclomethasone. as delivered by 
pediatric aerochamber and mask. significantly decrease the duration of paroxysmal 
coughing in young children with early pertussis. as compared with inhaled placebo? 
Research Design 
This study was a double-blind, randomized. placebo-controlled clinical 
trial. 
Sample Size Calculation: 
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The number of subjects required to show a significant result if, in fact. one 
exists is calculated as below. Estimates of the mean duration of paroxysmal coughing are 
taken from the 1973 paper by Zoumboulak.is et al., as previously described'' . In that 
study. mean duration of paroxysmal coughing was 19.3 days after onset of treatment (30 
days after the onset of disease). with a standard deviation of 6.5 days. It was arbitrarily 
decided that to be "clinically significant." a 25% decrease in the number of days to 
cessation of coughing would be required. The absolute number to which this corresponds, 
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is calculated from the mean duration of paroxysmal coughing as above (ie. 0.25 x 19.3 = 
4.825 days). 
Using these two nwnbers: the standard deviation of the mean duration of 
paroxysmal coughing and the level of change accepted as clinically significant, as 
calculated above, the sample size can be calculated from the formula for independent 
groups. Alpha has been set at 0.05 and beta has been set at 0.1 giving Z values of 1.65 
and 1.28 respectively. This gives a sample size of: 
2[ (za + zP)SDJ
2 
,ul-,u2 
= [(1.96 + 128)65]2 2 4.825 
= 38 subjects per group + 20% for anrition 
= 46 patients per group 
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Inclusion I Exclusion Criteria 
Subjects were eligible for inclusion in the study if they had the following 
characteristics: 
I) One of: 
a) A clinical history compatible with Bordetella pertussis infection. This must 
have included a history of paroxysmal coughing which may or may not have 
occurred following a period of catarrhal symptoms. The coughing paroxysms may 
or may not have been followed by vomiting, apnea, cyanosis. or an audible whoop. 
OR 
b) A positive culture for BordeteUa pertussis. 
2) Early disease (ie. less than 21 days of paroxysmal coughing). 
3) Age 0-7 years. 
Patients with the following characteristics were excluded: 
I) Refusal to participate. 
2) Presently on steroids for other purposes (eg. asthma or rheumatoid arthritis). 
3) History of active or quiescent pulmonary tuberculosis. 
4) History of untoward reaction to beclomethasone. 
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Subject Recruitment 
lt was originally planned that subjects would be identified entirely through 
referrals from the emergency room, staff pediatricians, pediatric residents and the 
microbiology laboratory at the Janeway Child Health Centre, StJohn's, NF. The Janeway 
is a 1 00-bed pediatric hospital serving the child and adolescent population of 
Newfoundland and Labrador. Its microbiology laboratory receives all samples of 
nasopharyngeal calciwn alginate swabs for isolation of pertussis. In addition to centre-
specific recruitment efforts, family and general practitioners were to be canvassed for 
patients by means of a letter campaign. In consideration of the rates of positive cultures 
from the microbiology laboratory and the numbers of patients seen presenting to the 
outpatient department in 1993, it was estimated that an accrual rate of 30 patients per year 
would be necessary in order to meet the enrollment requirements of the protocol. Given 
what investigators felt was a relatively benign intervention and the theoretical benefits 
potentially associated with this treatment. it was expected that such an accrual rate would 
be possible and, therefore, that the study was feasible. 
Unfortunately, recruitment proved to be the major obstacle in 
implementation of the trial. Review of interim data on reasons for the poor enrollment 
rates was completed by the primary investigator and members of the supervisory 
committee at various points during the investigation. These reviews revealed a number of 
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problem areas. As these were identified, strategies were implemented to try and resolve 
them. 
At the stan of the trial, the research protocol was presented to pediatricians 
and house-staff at the annual Pediatric Research Forum as an upcoming project. Despite 
this .. advance advertising," accrual was initially hindered most by poor referral rates. ln 
order to improve these, two letters were sent to pediatricians, children's emergency 
department physicians and the infection-control nurse at the Janeway Child Health Centre 
explaining the study and requesting that any patients admitted to the hospital or seen as 
outpatients, be referred for entry into the study. An example of one of these letters is 
included as Appendix A. The same letter was sent to pediatric residents training at the 
Janeway Child Health Centre. Additionally, letters were sent to each of the local general 
practitioners listed in the local research interest group asking for their cooperation in 
referring patients from their offices (see Appendix B). As a follow up to this letter, an 
information dinner on pertussis was used to educate local physicians about the study, and 
to ask them to refer their patients for enrollment. 
[n addition to efforts to improve recruitment from physician referrals, lab 
surveillance was also increased. The research nurse visited the microbiology laboratory 
every day and recorded the names of patients who had had nasopharyngeal swabs 
performed on the previous day. All patients for whom swabs for pertussis were collected 
were considered as being potential study candidates. Att.empts were made to contact these 
patients by telephone and to recruit them for the trial. A maximum of three telephone 
calls were made. Where answering machines were present, messages were left but 
seldom returned. Consequently, many potential subjects remained unreachable. 
If contacted, parents of potential subjects were asked a number of 
questions to detennine whether or not the children met inclusion and exclusion criteria. 
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ln particular, questions about asthma generated the most discussion as this disorder may 
be easily confused with pertussis, particularly if the child exhibits symptoms of the cough-
variant form of asthma. Consequently, parents of all potential subjects were asked if their 
children had asthma during the course of the screening interview. If the response was 
positive, they were asked to compare current symptoms with previous exacerbations of 
asthma If symptoms were the same then the potential subject was excluded on the basis 
that he or she did not meet the clinical case definition and was. therefore, ineligible for 
inclusion in the study. While many potential subjects were excluded by this method. 
overall, the increased laboratory surveillance resulted in the most significant increase in 
potential subjects. 
Another reason for low enrollment was the exclusion of subjects who had 
been coughing too long. The initial inclusion criteria had required that patients be 
coughing less than 14 days. After the enrollment of the first three patients, this was 
lengthened to 21 days when it was noticed that several of those subjects screened had 
been excluded due to protracted cough. This change in the protocol was not expected to 
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significantly affect the results because of the long duration of coughing in the disease. 
Despite this change, however, significant numbers of potential subjects still had to be 
excluded because they exhibited more than 21 days of paroxysmal coughing. In an effort 
to further address this problem by increasing the referrals of patients with early disease. 
Public Health Nurses {PHN's) were contacted and asked to refer any patients with clinical 
pertussis detected during their well-baby clinics or home visits. The fact that laboratory 
diagnosis was not required for admission into the study made this possible. 
In addition to the difficulties in referral, an unexpected reason for poor 
recruitment was parental refusal. Parents were consistently alarmed by the fact that the 
anti-inflammatory medication in the treatment arm of the study was a "steroid." The 
widespread discussion of anabolic steroids in the lay press, as well as an increasing public 
awareness of the systemic effects of oral corticosteroid preparations, perhaps made many 
parents wary of starting such a medication. This was particularly true in light of the 
absence of a guaranteed therapeutic response. This issue was addressed by providing 
detailed explanations of the lack of systemic side effects with short-term use of inhaled 
corticosteroids and the differences between glucocorticoids and anabolic steroids. 
Despite this, however, many parents remained hesitant to treat their children with such a 
medication. 
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Randomization 
Subjects successfully recruited were randomized by blocked, stratified 
randomization to either treatment or placebo, using a sealed envelope system. 
Stratification was based on age; group one consisted of those patients less than one year 
old and group two consisted of those one year old or older. Blocking was completed in 
groups of four. Stratification was done because of anticipated differences in disease 
severity in infants less than one year old. Blocking was done to ensure relative equality of 
the nwnbers of subjects randomized to each group, given the relatively low sample size 
required. 
Two sets of envelopes, one set white and one blue, were sequentially 
numbered and separated into groups of four. Interventions (drug vs. placebo) were 
assigned to particular envelopes by a disinterested third party using a draw system. This 
system worked as follows: for each group of four envelopes, one of four pieces of paper 
was selected from a "hat" containing two papers Labelled "A" and two papers labelled "B". 
The letter of the intervention selected was written on a card which was, in turn, placed 
inside the envelope and the envelope sealed. Each selected piece of paper was kept to one 
side until all of the pieces in the "hat" had been dra~ and thus, all of the envelopes in 
the group of four had been assigned a letter. Papers were then returned to the "hat" and 
the process was repeated with the next four envelopes until all envelopes had been filled. 
All envelopes were then given to the pharmacist. At the start of the study the phannacist 
39 
was asked to choose which intervention would be represented by which letter. The letter 
code was known only to him until the end of the study. Thus. within each group of four. 
two envelopes specified assigrunent to the placebo group and two specified assignment to 
the treatment group, thereby accomplishing effective blocking. 
After consenting to participate in the study, subjects were assigned to the 
treatment option in a particular blue or white envelope based on their age and sequence of 
enrollment. The appropriate envelope was ordered by an investigator and selected by the 
pharmacist. Patients' records denoted only the colour and number of the envelope 
containing the letter of the intervention to which they had been assigned. Based on the 
letter in the envelope, the phannacist dispensed the assigned drug or placebo. Due to 
difficulties in obtaining unlabelled canisters, usual labels were removed from all canisters 
by the pharmacist and replaced with a standardized typed white label listing the patient's 
initials, study identification number, and the words "use as directed." The canisters were 
dispensed in identical unlabelled wltite delivery systems. After the initial interview and 
device-use teaching had been done, the medication was given to the parent to administer. 
In most cases, the initial dose was given by the research nurse in the presence of the 
parent as a demonstration of proper technique. 
Intervention 
Subjects received one of: 
-Beclomethasone (Beclovent ®) 100 meg (2 puffs of 50mcglpuff preparation) 
three times daily 
OR 
-Inhaled placebo 2 puffs three times daily 
All medications were administered by aerochamber™ and mask. This regimen was 
prescribed for a total of 30 days. 
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All subjects in both groups were also started on erythromycin therapy for 
14 days if it had not already been prescribed by their primary care physician. 
Compliance 
Compliance with the treatment regimen was assessed by weighing 
canisters before and after treatment had ended. The change in weight for each patient's 
canister was compared with expected changes derived from two test canisters used in the 
phannacy. Based on this, an estimate of compliance was reached for each patient. 
Outcome Measures 
The primary outcome measure for this study was the duration of 
paroxysmal coughing episodes after treatment was begun. 
All of the following were considered secondary outcome measures: 
-change in daily cough bout frequency before and after treatment 
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-complications of pertussis including seizures. pneumonia, and encephalitis (chest 
X-ray completion and findings were recorded from the chart in an effort to 
document pneumonias more clearly) 
-complications of treatment including facial ras~ voice changes, and oral 
candidiasis 
-need for hospitalization and cumulative days in hospital 
-parental perceptions of disease as measured by a questionnaire 
A number of baseline characteristics were also recorded to ensure potential confounders 
could be controlled for in the analysis. These included sex, age, duration of coughing and 
duration of erythromycin therapy at study entry, the presence of atopic diseases (asthma, 
allergies or eczema), and whether or not the child attended daycare. 
Definitions 
• duration of coughing- the interval in days from onset of treatment to the point 
when patient is experiencing no more than one coughing episode daily, as reported 
by the parent 
• cough bout frequency - the number of coughing episodes in a defined time period 
as reported by the parent 
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Means of Measurement 
The primary outcome variable was assessed by means of a diary which was 
kept by the parent (see Appendix C). Parents were also contacted by phone on days 14, 
16. 18, 20. 22, 24. and at exit from the study on day 30 to determine the child's progress 
and to encourage diary completion. A questionnaire (Appendix D) was administered by 
phone to the child's parents on these days to assess secondary outcomes. Times for 
interviews are clustered around expected mean duration of illness as reported in the 
Zoumboulakis et al. study 11 . 
The remaining secondary outcome variables were recorded as follows: 
• complications of pertussis were taken from the hospital chart and from the 
parental questionnaire 
• number of days in hospital were taken from the parental questionnaire and 
confirmed from the patient's chart where applicable 
• parental perceptions of disease were obtained from a questionnaire administered to 
parents at the end of treatment 
• the frequency of treatment complications including facial rash and/or oral 
candidiasis was obtained from parental reports as recorded on the exit 
questionnaire 
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Data Analysis 
The primary outcome variable for this study was the duration of 
paroxysmal coughing. Consequently, null and alternate hypotheses were defmed as 
follows: Ho: J.11 = J.L2 and Ha: J.L1 ~ J.L2 where J.11 represented the mean duration of coughing 
for the treatment group and J.L2 represented the mean duration of coughing for the placebo 
group. Data were analysed using an unpaired, two-tailed t-test. However. since the 
primary outcome variable was essentially the time to the development of a particular 
even~ namely. cessation of coughing, survival analysis and the log rank test was an 
equally appropriate test and was also used in data analysis. A twenty-five per cent change 
was arbitrarily selected as the level at which a change could be considered clinically 
significant. Consequently, any conclusions to be made from the data were made in this 
context. 
In addition to the primary outcome variable, a number of non-parametric 
variables have been defined above. Frequency data were analysed using the Chi-square 
test where appropriate. The type I error was again set at a level of0.05. Since this was a 
randomized study and consequently, by defmition, any differences between the treatment 
and control groups will have occurred by chance, demographic variables were not 
statistically compared. 
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The problems of repeated significance testing were acknowledged and it 
was understood that any statistically significant differences evident among the secondary 
outcome variables would be useful as pointers for possible future areas of study only. 
Statistical Support 
The SPSS-X statistical package was used for data analysis. 
Ethical CoDJiderations 
Attempts were made to protect the rights of the subjects. Parents or legal 
guardians were given an explanation letter prior to enrollment of their child in the study 
explaining the purpose of the investigation. expected length of participation, and the fact 
that they could withdraw their child from the study at any time. Parents were asked to 
give verbal and written consent for their child to participate and were assured of the 
confidentiality of information given. A copy of the consent fonn is attached as Appendix 
E. 
In a further attempt to protect confidentiality. subjects names were not used 
on the data collection forms or questionnaires. Instead, subjects were identified by a code 
number. Any forms identifying the subject were kept under lock and key, and were only 
accessible by the researchers and the research nurse. The pharmacist. who dispensed the 
study medication. also had a list of all those participating in the trial which was kept in a 
locked drawer in the pharmacy. 
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The risks associated with the study were minimal and were essentially 
limited to the risks associated with short-term inhaled steroid use. These include local 
reactions resulting from irritation or suppression of local immunity and the small 
possibility of an untoward reaction to the medication. Systemic effects in short term use 
are negligible. Parents were informed of these possibilities prior to their child's 
enrollment. Also, parents were advised to wipe children's faces with a damp cloth after 
each treatment to avoid the deposition of significant amounts of drug on the child's face, 
thereby reducing reactions. Those old enough to rinse their mouths with water after 
treatment were also asked to do so in an effort to reduce the incidence of oral candidiasis 
as a complication . 
Parents or guardians were offered access to the results of the study if they 
desired, and the researcher was available at all times during the study to answer questions 
should they have arisen. Attending physicians were informed of their patients' enrollment 
by means of a lett·er (see Appendix F). 
Finally, the proposal was sent to the Human Investigation Committee at 
Memorial University of Newfoundland's Faculty of Medicine, as well as the Janeway 
Child Health Centre for approval. Both committees approved the protocol prior to its 
implementation. Copies of the approval letters are attached as Appendix G. 
Budget 
A copy of the budget for this project is included as Appendix H. 
CHAPTER3 
Problems and Solutions 
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Throughout the planning and implementation of this project, a number of 
problems were encountered. Each was addressed and a specific strategy employed to 
solve it In the section that follows, the problems encountered will be outlined and the 
methods used to attempt to solve them will be detailed. For clarity, these have been 
grouped as: problems related to the selection of an outcome variable. problems in 
recruitment, and problems with dropout. 
Selecting a Primary Outcome Variable 
The initial. and perhaps most time-consuming problem in the design of 
this study, was selecting an outcome variable. As in any clinical trial, it was important to 
choose a variable that wouJd have both clinical relevance and practical application. This 
meant validly and reliably measuring an important clinical effect which was expressed by 
virtually all patients. Such an ideal parameter proved to be difficult to define. 
The Initial Primary Outcome Variable 
As indicated in the introduction. pertuSsis is an illness characterized by 
recurrent bouts of paroxysmal coughing which are sometimes, but not always, followed 
by a whoop• . While most studies on pertussis had measured the total number of coughs, 
whoops, and vomiting episodes per day, most of these investigations had been conducted 
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in hospitals where a nurse or other professional caregiver may have been assigned to 
docwnent each episode of coughing~ vomiting or whooping 71•11.c·15• With the move 
towards ambulatory pediatric care, most patients with pertussis are now cared for on an 
outpatient basis "· 16 , making this approach no longer feasible. Since reliability and 
validity were initially felt by the primary investigator to be more important than 
practicality, the absolute number of coughs in a 4 hour period was initially selected as the 
outcome variable of choice. It was thought that this variable was both clinically relevant 
to the patient and could be measured with relative ease, accuracy, and reliability while the 
patient was sleeping. This seemed to make it a practical outcome to assess. 
Defining Cough 
Having chosen an outcome variable, however, the investigators were then 
faced with the absence of a clear definition for a cough. For example, was a cough a 
single expiratory burst of sound or was it a series of such bursts? If the former were true, 
how could these bursts be measured with any accuracy? If the latter were correc~ how 
long between cough series was enough to denote a second episode? The questions 
appeared to multiply the more the issue was considered. 
Physiologically, cough can be defined easily as a forced expiratory 
manoeuver, differing from forced expiration by starting with a closed glottis which is 
opened suddenly after intrathoracic pressure has built up, and terminating with reclosure 
of the glottis 17• The clinical definition is much more difficult because the exact moment 
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that the glottis opens and closes is difficult to determine. Further, if one doesn't have the 
benefit of looking at the patient, distinguishing a cough from a grunt (an important 
consideration in the pediatric population!) can be a difficult thing. The literature was 
equally unhelpful in answering this question. Hence, the investigators settled on a 
compromise definition which defined cough as any detectable single, discrete. sudden. 
tussive, expiratory sound. whether occurring in a group or individually. A "coughing 
bout" was then defined as a temporally related group of coughs without an intervening 
inspiratory sound and "cough frequency" as the number of coughs in a defined time 
period 
Measurement of Coughs 
Having defined the variables to be studied, the next problem was how to 
measure thern with the maximum degree of reliability and validity. Broomhall and 
Herxheimer bad suggested that studies of treatments for pertussis consider using a 
sound-triggered recording apparatus for cough counting 59 • We did not have any expertise 
in this method at our institution or in the local area In order to resolve the problem, a 
literature search was undertaken to determine whether other investigators had had any 
success in using this method in the past. Following a Medline ™ search using both 
OVID® and Sliver Platter® software, a single paper was identified. This publication by 
Loudon and Romans identified a recording system which could be used for cough-
monitoring a. It employed a complicated procedure using two tape recorders fed by a 
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single microphone. The first recorder was modified to "hold" the sound in a three second 
"delay loop" while the second recorder was activated. After travelling through the delay 
loop, the sound in the first tape recorder was then recorded onto the second one. "The net 
effect was as though the second tape recorder had been started three seconds before a 
cough or similar sound. recorded the sound, and then switched itself off again" 11 0 Or. 
Loudon went on to use this system for recording cough frequencies in patients with such 
conditions as pneumonia, pulmonary tuberculosis and chronic obstructive lung disease. 
In a second paper he states that using this equipment. eight hours of coughing in two 
patients could be read in l-20 minutes, making it a very practical as well as valid tool 19 0 
While too complex for our study, this work provided a starting point for 
designing a new instrument to measure cough. Additionally, it allowed us to contact Dr. 
Loudon who subsequently provided other references and some personal suggestions 
which eventually proved very helpful. Desirable qualities we identified for the ideal 
outcome-measuring instrument were that it was to be compact, simple to use, able to 
record for at least 4 hours without need for intervention, specific for coughs, able to give 
visual output or recording, sensitive over a wide range of frequencies and intensities and 
inexpensive. Such an instrument would allow maximal information to be extracted in a 
minimal amount of time. Constructing such a utopian machine proved to be considerably 
more difficult. 
However, in conjunction with the biomedical department at the Janeway 
Child Health Centre in St. John's, a device was designed and a pilot study initiated to test 
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the new instrument. The machine consisted of a regular cassette tape deck equipped with 
an omnidirectional microphone which was placed next to the child's bed. A "sound 
sensor," which was built into the circuit, was set to activate the tape recorder in response 
to any sound between 50 and 1500 Hertz which was picked up by the microphone. Once 
activated, the machine would continue to record for a total of two minutes and then 
deactivate. Any new sound was capable of reactivating it to record again. Sensory level, 
or the intensity of sound required to trigger the machine to record was adjustable using a 
small button on the front of the instrument A circuit diagram of the entire setup is 
included as Appendix I. 
Sample Size 
With a primary outcome variable and a potential measuring instrument, 
the next hurdle to overcome was the calculation of a sample size. Since the statistical 
analysis of the trial results would involve the comparison of the differences between two 
means, in order to calculate a sample size one needed to know the mean and standard 
deviation of the 4 hour cough frequency in the population to be studied. As this outcome 
bad not been used previously, no such statistics were available. ln order to estimate them, 
as well as test the measuring instrument, a pilot study was designed. 
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Pilot Study 
A pilot study was designed and implemented after approval by the ethics 
committees at Memorial University of Newfoundland and the Janeway Child Health 
Centre. The study recruited inpatients with clinical pertussis and recorded coughs over a 
4 hour sampling period. Copies of the entire protocol, the consent form used, and 
approval letters from both the Human Investigation Committees at Memorial University 
and the Janeway Child Health Centre are included as Appendix J for more detailed 
information. The initial attempt met with failure when the tape recorder did not activate 
with coughs. This was attributed to a malfunction in the circuit A second attempt was 
made on the next night. Unfortunately, this also met with variable technical success with 
the recorder working only part of the time and inconsistently activating with coughs. The 
high maintenance required for this syste~ along with its bulkiness, made it impractical 
for parents to use on their own at home. Consequently, the model was abandoned. 
Based on a suggestion by Dr. Loudon (personal communication, March 
1994) a commercial solution to these problems was found in a hand-held dictaphone. A 
Radio ShackTM voice-activated dictaphone was purchased and used in monitoring a 
single patient on two consecutive nights. This machine circumvented not only the 
technical difficulties experienced with the "homemade" model, but was also compact 
enough to fit into a shirt pocket. This made it the ideal size for parents to carry home and 
use. Additionally, setup was very easy with the press of a single button required for 
activation. 
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Using the Radio Shackn.c model~ a single patient had coughs recorded for 
two consecutive nights. The machine appeared to work well with activation occurring 
consistently in response to coughing episodes. Unfortunately, however. it also activated 
with even quiet extraneous noises in the environment. This made interpretation of the 
tape exceedingly time consuming, with requirements of up to three hours of review time 
for each night of study. In an investigation which planned thirty nights of observation in 
each of 64 patients, such a time requirement virtually precluded its use entirely. 
Additionally, the machine did not provide enough sound resolution to allow clear 
distinction between different noises such as grunting and coughing. This would have 
serious implications for the reliability of the outcomes obtained by this method. Because 
of these difficulties, this measuring device, and eventually, this outcome measure, were 
abandoned. 
Selecting Another Primary Outcome Variable 
Given the difficulties experienced, as outlined above, measured cough 
frequency was abandoned as a potential outcome measure and the investigators returned 
to parental reports of cough frequency as the most practical alternative. Data collection 
sheets were subsequently designed which asked the parents to tally the number of coughs 
the child had each day. In cases where a child was attending school, the parent was 
asked to give the cough-record (Appendix A) to the teacher to keep during the day. The 
problems with parental recall and supervision intrinsic to such an outcome were 
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acknowledged. However, given that the treatments were to be randomized, it was felt 
that these influences would most likely be distributed evenly across both groups and that 
their impact on the flnal results would thus be minimized. 
Recruitment 
Having decided on a new primary outcome variable and a means of 
measuring it, it was possible to move on to the implementation of the actual investigation. 
The most significant problem experienced during this phase, and the most important in 
relation to the overall results, was the difficulty experienced in recruiting patients for the 
study. Of the 560 potential subjects that were contacted, only 23 patients enrolled in the 
study and of these, only 18 stayed in the study long enough to provide usable data. There 
were a number of reasons for this. As each was identified, a strategy was put in place to 
try and minimize its effect. These strategies have been previously listed in the methods 
section. It is the details of their implementation and their relative effectiveness that is 
described here. 
Initially, recruitment was hindered by poor referral rates. In order to 
improve these, two letters were sent to pediatricians and children • s emergency department 
physicians explaining the study and requesting that any patients admitted to the hospital 
or seen as outpatients, be referred for entry into the study. A similar letter was sent to 
pediatric residents training at the Janeway Child Health Centre. Additionally, letters were 
sent to each of the local general practitioners listed in the local research interest group 
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asking for their cooperation in referring patients from their offices. As a follow up to this 
letter, an information dinner on pertussis was used to educate local physicians about the 
study. and to ask them to refer their patients for enrollment. 
While letters requesting referrals resulted in minimal improvement in 
recruitment from pediatric resident referrals. referrals from pediatricians, emergency 
room physicians and general pediatricians remained low. Additionally, the information 
dinner had the opposite effect from that desired in that some physicians began putting 
their pertussis patients on inhaled steroids without enrolling them in the trial. This may 
explain the high proportion of patients with positive pertussis swabs who had to be 
excluded from the study because they were already on steroids. The particular physicians 
concerned were telephoned and asked to avoid this practice if possible. While this did 
improve the situation. a number of potential subjects were lost. 
In addition to efforts to improve recruitment from physician referrals, lab 
surveillance was also increased. The research nurse visited the microbiology laboratory 
every day and recorded the names of patients who had nasopharyngeal swabs collected on 
the previous day. All of these patients were considered potential study candidates. 
Attempts were made to contact these patients and recruit them for the trial. This resulted 
in an increase in potential subjects. 
Another reason for low enrollment was the exclusion of subjects with 
more than 21 days of paroxysmal coughing. In an effort to increase the referrals of 
patients with early disease, Public Health Nurses (PHN's) were contacted and asked to 
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refer any patients with clinical pertussis detected during their weU-baby clinics or home 
visits. The fact that laboratory diagnosis was not required for admission into the study 
made this possible. Unfortunately, PHN subject identification did not improve the 
enrollment rate significantly. 
In addition to the difficulties in referral. an Wlexpected reason for poor 
recruitment was parental refusal. Parents were consistently alarmed by the fact that the 
anti-inflammatory medication in the treatment arm of the study was a "steroid." The 
widespread discussion of anabolic steroids in the lay press, as well as an increasing public 
awareness of the systemic effects of oral corticosteroid preparations, perhaps made many 
parents wary of starting such a medication. This was particularly true in light of the 
absence of a guaranteed therapeutic response. This issue was addressed by providing 
detailed explanations of the lack of systemic side effects with short-term use of inhaled 
corticosteroids and the differences between glucocorticoids and anabolic steroids. 
Despite this, however, many parents remained hesitant to treat their children with such a 
medication. Similarly, the idea of a placebo discouraged some parents from having their 
child randomized. 
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Drop Out 
The final problem experienced was that of drop-out. While 23 patients 
were initially recruited for the study, only 18 provided useable data. Reasons for dropout 
will be detailed in the results chapter and will not be reiterated. In order to make 
maximal use of all available data. when a parent indicat.ed that he or she wanted to 
remove a child from the study, contact was made with him or her by the research nurse. 
Parents were asked to return their children's puffers and cough diaries which could have 
been included in a survival analysis. Unfortunately, none of the parents whose children 
did not complete the study agreed to do so. This occurred despite repeated calls from the 
research nurse, as well as offers to pick up puffers and diaries from the subjects' homes. 
In these ways, problems encountered by the trial were addressed and the 
most reasonable solutions which circumstances allowed were proposed. In some cases, 
these solutions proved acceptable and in others, the situation remained suboptimal. 
Despite the persistence of such problems, however, a number of children were 
successfully enrolled in the trial and data was collected from them. The next chapter 
describes the group of subjects enrolled and details the data they provided. 
Subjects 
CHAPTER4 
Results 
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This study was conducted in two periods from January 1, 1995 to April 30, 
1995 and from September 1, 1995 to March 28, 1996. These periods were chosen in an 
attempt to maximize use of available funding through employment of a research nurse 
only during those periods when the incidence of pertussis was high. Despite the reported 
lack of seasonal variation by some investigators•, the Janeway microbiology records 
showed that the majority of cases in the local area occurred during the fall and winter 
months of each year (James Fleming, unpublished data). During the interval of study, 
560 referrals, representing 539 patients, were made to study investigators (21 subjects had 
several swabs done for pertussis during the course of the study period and so were 
referred twice). Of these refenals, 369 were successfully contacted. The others could not 
be reached by telephone. Of those contacted, the commonest reason for exclusion was 
the failure of referred patients to meet the case definition of pertussis. One-hundred-and-
fifty-nine referred subjects (28.4%) were excluded for this reason. Sixty-two referrals 
( 11 .1%) had been coughing too long to qualify for study entry. Another 61 referrals 
(1 0.9%) were excluded because they were already on inhaled steroids. Parents of 31 
referrals (5.5%) refused entry of their children into the trial. Thirteen referred subjects 
(2.3%) were older than 7 years and therefore did not meet inclusion criteria Parents of 
58 
twelve referred children (2.1 %) reported living too far from the study centre to enter the 
trial. Information was not recorded on the reason for exclusion of 8 referrals, comprising 
1.4% of the total. These numbers are summarized in table 4.1 and depicted graphically in 
figure 4.1. The remaining 23 subjects (4.2%) were entered in the trial. 
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Table 4.1 Reasons For Exclusion Of Referrals Not Entered In Trial 
Reason for Exclusion Frequency Perc:entage of AU 
Attempts 
unable to reach 191 34.1 
failure to meet case definition 159 28.4 
coughing too long 62 11.1 
on steroids 61 10.9 
refused 31 5.5 
age>7years 13 2.3 
location out of town 12 2.1 
information not recorded 8 1.4 
Total 537 95.8 
200 ' 
0 t -
U1R wrong dx ateroida refused 
~notcntm:d 
Figure 4.1 Reasons for Exclusion of Subjeds Not Entered in Trial 
Legend: UTR= unable to reach, wrong dx =did not meet case definition, 
cough = coughing too long, steroids = already on steroids, refused = refused entry, 
too old = older than 8 years, location = lived too far from study centre, 
missing = reason not recorded 
too old location -
. 
0\ 
0 
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The total number of swabs done by the Janeway microbiology lab during 
the period of study is unknown, as no record of that information is kept. However. the 
total number of positive results reported to the Department of Health during the study 
period was 94 (James Fleming, unpublished data). Of these, attempts were made to 
contact 55. Those with positive swabs who were not contacted included those who were 
known to be from out of to~ those whose age appeared on the requisition and who were 
older than 7 years, and those who were missed before enhancement of the laboratory 
surveillance process. The swab results of all potential subjects referred to the trial, along 
with their disposal, are recorded numerically in table 4.2 and depicted graphically in 
figure 4.2. Information on swab results was not available for 26 cases and information 
on reason for exclusion was not available in 8 cases, thus accounting for the total number 
of patients referred. 
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Table 4.2 Outcome Of Referrals According to Swab Results 
Outcome of Swab Results 
Referrals 
Negative Positive Missing 
unable to reach 186 3 2 
wrong diagnosis 153 0 6 
coughingtoolong 48 8 6 
on steroids 43 15 3 
refused 24 4 3 
location out of town 11 1 0 
age> 7 years 6 3 4 
entered in study 6 15 2 
missing 2 6 0 
Totals 479 ss 26 
200 , . 
1)0 
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wroos dx wugh steroids refused too old atldy location Missins 
disposal 
Figure 4.2 Disposal of Referred Patients 
Legend: UTR= unable to reach, wrong dx = did not meet case definition, 
cough ;;;:; coughing too long, steroids = already on steroids, refused - refused entry, 
too old= older than 8 years, study= entered in study, location= lived too far from study centre, 
missing = disposal not recorded 
NEal Swab Result 
·~satiw 
.positiw 
~Miuioa 
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Referral Sources 
Examining the referral source for those in each group shows that 7 
subjects in the beclomethasone group were referred by the laboratory with the other 2 
subjects referred by a resident and a general practitioner. In the placebo group, 3 subjects 
were identified through the emergency department, 3 by the laboratory and 1 each from a 
resident, a pediatrician and a general practitioner. No patients in the beclomethasone 
group were referred by pediatricians or the emergency department The source of referral 
for all patients in both groups is shown in table 4.3. 
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Table 4.3 Referral Sources 
Referral Source Placebo Beclomethasone 
laboratory 3 7 
emergency 3 0 
pediatrician 1 0 
resident 1 1 
general practitioner l 1 
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Of patients entered in the study, five withdrew before the end of treatment 
and before any useable data could be collected. Two patients exited before completion of 
treatment because the nasal swab subsequently came back negative and parents were 
unwilling to continue with the medication. Another patient failed to return the cough 
diary, making estimation of the time to disappearance of cough impossible. A fourth 
patient exited 2 days following initiation of treatment because of a perceived worsening 
of cough on the study medication. One patient was withdrawn by the parents after an 
initial period of perceived benefit, because the child appeared to the parents to become 
worse and the mother was concerned about the effects of steroids. All patients exiting 
failed to return the cough diary, making calculations impossible. Of patients who 
dropped out after randomization, two had been assigned to receive placebo and three had 
been assigned to receive beclomethasone. 
Baseline Characteristics 
Of those patients completing the trial, 9 received beclomethasone and 9 
received placebo. Comparison of group characteristics at baseline is provided as table 
4.4. 
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Table 4.4 Baseline Group Characteristics 
Characteristic Placebo Beclomethasooe 
age in months 32.6 (4-95) 44.5 (2-90) 
mean (range) 
days coughing at entry 13.1 (3-21) 14.9 (8-21) 
mean (range) 
days of erythromycin 3.8 (0-8) 5.1 (0-14) 
mean (range) 
sex male -4 male- 5 
female- 5 female- 4 
~(no.ofpatien~) 1 0 
allergies (no. of 1 0 
patients) 
eczema (no. ofpatien~) 4 3 
daycare attendance 2 3 
(no. of patien~) 
68 
As shown in table 4.4, groups were very similar in most characteristics 
with the exception of age, the beclomethasone group being slightly older overall than the 
placebo group. Only 4 patients (22%) were less than 12 months old at entry into the trial. 
The overall average duration of coughing at entry into the study was 14 days, with means 
for the respective treatment groups shown in the table. Similarly, the overall mean 
duration of erythromycin therapy at study entry was 4.4 days, with little difference seen 
between the two study groups. Approximately 28% of patients entered in the trial had 
been treated for their illness with antibiotics other than erythromycin. Only one subject 
had not been treated with any antibiotics at study entry. Another 28% of subjects had also 
been treated with medication other than antibiotics. Of this latter group, two patients 
were on oral orciprenaline (Alupent®), one patient was taking an over-the-counter cough 
preparation containing dextromethorphan, one patient was taking acetaminophen for 
perceived teething-related pain and one patient was on sodiwn sulamyd 10% eye drops 
for purulent conjunctivitis. The distribution of these patients between the two groups was 
similar. Nearly half of recruited subjects reported some evidence of atopic disease with 8 
subjects reporting at least one of asthma, allergies or eczema in the past. The relative 
distribution of subjects with each of these problems is also presented in table 4.4. 
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Baseline Symptoms and Laboratory Findings 
Groups were assessed at the time of entry into the trial to determine 
whether baseline differences in symptoms or Laboratory findings existed. All were 
coughing at entry into the srudy since this was an inclusion criterion. Further, 16 subjects 
exhibited at least one of the relatively .. pertussis-specific,. symptoms of vomiting after 
coughing, whooping. apneas, or cyanosis. Overall. 72% of subjects had vomiting during 
the course of their illness, 72 % exhibited whooping, 17% had apneas and 17% had 
parentally reported cyanotic spells. Interestingly, parents reported fever in one third of 
subjects recruited for the trial. The distribution of symptoms at baseline between the two 
groups are provided as table 4.5. The mean number of coughs per day (with 95% 
confidence interval (CI)) at initiation of treatment in the placebo group was 11.8 (6.6, 
17.0) and 22.3 (6.8, 37.9) in the group treated with beclomethasone. 
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Table 4.5 Baseline Symptom Frequencies 
Symptom Placebo Group Beclometbasone Group 
number of patients(%) number of patients (%,) 
Vomiting 7 (39) 6 (33) 
Whooping 6 (33) 7 (39) 
Apneas 1 (6) 2 (11) 
Cyanosis 2 (11) 1 (6) 
Fever 5 (28) 1 (6) 
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Pneumonia was reported in only one subject at the beginning of the study 
with chest X-rays performed in 7 (38%) subjects. Two subjects had chest X-rays reponed 
as showing peribronchial thickening without evidence of atelectasis or pneumonia. One 
was being treated with placebo and one with beclomethasone. The subject who was 
treated with placebo had a positive pertussis swab. The beclomethasone-treated subject 
subsequently grew adenovirus from the nasopharyngeal swab. The rest of the X-rays 
were reponed as normal. 
White blood cell counts were available in only 3 subjects in whom they 
were not elevated with the average being 12.4 in the placebo group. The single subject in 
the beclomethasone group who had a WBC count done had a count of 13.4. Lymphocyte 
percentages were mildly elevated with the average percentage being 0.65 in the placebo 
group. The subject treated with beclomethasone had a lymphocyte percentage of0.66. 
Follow-up Calls 
Prior to completion of the study, six follow-up telephone calls were made. 
The primary purpose of these, in addition to encouraging parents to continue 
participation, was to assess both progression and complications of the disease. and 
potential side effects of the medications. At the initial follow-up call made at day 14 after 
entry into the study, only 1 child had stopped coughing. This subject was receiving 
placebo. One subject in the beclomethasone group was experiencing apneas and one 
subject in the placebo group was experiencing fever. Two subjects, one in each group, 
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were still experiencing vomiting episodes and one subject in the beclomethasone group 
was still having whoops. A single parent reported pneumonia in a child treated with 
placebo. No parent reported seizures. 1bree subjects (2 from the placebo group and 1 
from the beclomethasone group) had experienced other complications which had been 
attributed to whooping cough. One subject in the placebo group complained of sore ears 
and throat which was treated by the general practitioner with amoxicillin. This otitis 
persisted throughout the duration of the study and eventually resulted in the subject being 
treated with an antihistamine and an erythromycin I sulfasoxizole mixture by the general 
practitioner. A second subject in the placebo group complained of upper respiratory tract 
infection but was not treated with any new medications. The subject in the 
beclomethasone group complained of "the flu" which was also treated with amoxicillin. 
No subject bad experienced thrush, noticeable change in voice or facial rash at the time of 
the fiiSt follow-up call. A single subject in the placebo group did report development of 
diarrhea which had been attributed to the study medication, but which was likely due to 
the erythromycin. 
A second follow-up call was made on day 16. At this time no subject was 
experiencing apneas, blue spells, fever, vomiting or whoop. Again, however, all but one 
subject continued to cough. No new subjects bad developed pneumonia or experienced 
seizures. One subject who had been randomized to the placebo group had developed 
thrush which was being treated with mycostatin, but no one reported any change in voice 
or facial rash. A second subject in this group was experiencing mild nausea with 
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occasional vomiting not related to cough. No other potential drug effects were noted by 
parents. 
A third follow-up call was made on day 18. At this point, 4 subjects had 
stopped coughing (2 from each group) while other symptoms remained unchanged. No 
subject reported any new complications of their disease and there were no new instances 
of thrus~ change in voice, facial rash or other symptoms potentially attributable to the 
medication. 
At the time of the fourth follow-up call on day 20, one of the subjects in 
the placebo group who had stopped coughing, had restarted. Otherwise, the distribution 
of pertussis symptoms was unchanged. No new ,complications of the disease or treatment 
were reported. 
The fifth follow-up call on day 22 saw a switch from the previous in that 
one of the subjects in the beclomethasone group had restarted coughing having previously 
stopped. Again, other symptoms were unchanged. The sixth and final call on day 24 was 
similar in that again, no new symptoms or complications had been reported. At that time 
only 5 patients had stopped coughing completely. 1bree were from the placebo group 
while 2 were from the beclometh.asone group. 
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Cough Duration 
The primary outcome variable was the time to cessation of coughing. This 
was assessed from patient diaries kept by the parents and other caregivers for the subjects 
in the study. A plot of the mean number of coughs for each day of the study for both 
groups is provided as figure 4.3. The sudden rise in the number of coughs in the placebo 
group on day 26 is due to one subject who coughed 224 times on that day. This subject 
had a negative pertussis swab and subsequently grew adenovirus. With this outlier 
removed. the mean is 5. 7. 
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In the beclomethasone group the mean time to cough cessation was 26.8 
days while the placebo group had a mean value of21.4 days. Student's t-test for the 
difference between these two means gave a p-value of0.2 with a 95% confidence interval 
for the difference of ( -14.313, 3.646) showing that the result was not significant at the 
ps0.05 level. This variable was also assessed with survival analysis using the Kaplan-
Meier method. Results of that analysis are shown graphically in figure 4.4. From the 
curves it appeared as though there was a trend towards better performance in the placebo 
group. Analysis of the curves using the log rank test, however, confirms the results of the 
t-test and shows no significant difference between groups at the « = 0.05 level (p = 0.8). 
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Since the beclomethasone-treated group started with a greater number of 
coughs per day, the time it took for members of each group to attain a 25% decrease in 
number of coughs was also assessed in an effort to minimize the inequality. The mean 
time to achieve this reduction in coughing for the placebo group was 5.9 days and for the 
beclomethasone group was 4.4 days. Again, Student's t-test failed to show a significant 
difference between the groups (p= 0.19). This is again shown graphically as a Kaplan-
Meier curve in figure 4.5. The log rank. test confirms the absence of a significant 
difference between the two curves (p = 0.23). 
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Due to the use of a clinical case defmition for pertussis. the possibility 
exists that some subjects without true pertussis infection were included in the trial. To 
negate the effects of this possibility on the study conclusions, data on just those subjects 
with positive pertussis swabs were re-analysed with the others removed. The adjusted 
mean number of days to cessation of coughing was 27.6 for the treatment group and 24.6 
for the placebo group. Results of Student's t-test (p = 0.61 ) and survival analysis (log 
rank test - p = 0.61 ) confmned the earlier fmdings that showed no difference between the 
groups. Grapb.ic depiction of this is included as figure 4.6. 
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Compliance 
Compliance was assessed by weighing canisters before and after 
completion of therapy. Expected weight change was based on a test use of both a 
beclomethasone and placebo canister. The actual change in weight was divided by the 
expected change in weight to give an estimate of compliance. In all, 5 subjects who 
completed the study failed to return their canisters. Using the method described above on 
data from those who did return their medications gave a mean overall compliance rate of 
84%. Breaking it down by groups shows an average compliance rate (95% Cl) of 86.1% 
(66%, 106%) in the placebo group and 81.8% (61%, 102%) in the beclomethasone group. 
However, of the 5 subjects who did not return their inhalers, 4 were from the 
beclomethasone group and I was from the placebo group. Multiple telephone calls were 
made to parents of subjects for whom inhalers bad not been returne~ asking them to 
return the devices. In some cases, offers were made to pick up the inhalers from the 
subjects' homes. No inhalers were retrieved in this manner. 
Disease Impact and Severity 
Parents were all interviewed at exit from the study to determine their 
opinion of the disease process and its impact on their families. All were asked to rate the 
disease severity on a five point Likert scale ranging from "mild (like a cold)" to "severe 
(life-threatening)." They were also asked to report whether the disease had resulted in 
lack of sleep for the child or themselves. The economic impact of the disease was 
83 
assessed by asking whether any of the primary caregivers had been required to take time 
off work because of the disease. Results are provided in tables 4.6 and 4. 7 and showed 
that most parents in both groups considered whooping cough to be a moderate to 
moderate-severe disease. Minor group differences were not statistically significantly 
different. Virtually all parents reported that both they and their children had lost sleep 
due to the illness and minimal differences between groups were not statistically 
significant. Few parents reported lost work time as a result of the illness. All those who 
did lose work time due to the illness were from the beclomethasone group. Results were 
not statistically significantly different using the Chi Square test. 
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Table 4.6 lmpact of Disease Questionnaire Results 
Quality Assessed Placebo Beclometbasone Total 
n(%) n(%) n (%) 
sleep loss (child) 8 (44) 9(50) 17 (94) 
sleep loss (parent) 6 (38) 9(56) 15 (83) 
time off work 0 3 (17) 3 (17) 
Table 4.7 Disease Severity as Rated by Parents 
Disease Severity Placebo Beclometbasone Total* 
D (o/o) D (%,) n(%) 
mild (like a cold) 0 l (6) 1 (6) 
mild-moderate 0 1 (6) 1 (6) 
moderate 3 (17) 4(22) 7 (39) 
moderate-severe 6 (33) 3 (17) 9 (50) 
severe (life 0 0 0 
threatening) 
• Total adds to more than 100% because of rounding 
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CHAPTERS 
Discussion 
Recruitment Efforts 
The results of this study are primarily limited by the low numbers of 
subjects recruited for entry. The reasons for the poor accrual rate are varied but problems 
may be considered in three groups. These include problems stemming from the trial 
desi~ problems resulting from the disease under study, and problems related to the 
population itself. 
Design Problems 
From the point of view of trial design. it became apparent very early that 
estimates of the numbers of subjects who could be enrolled each month were high. Such 
overestimation is not uncommon in clinical trials90•9 ' . In our case, the problem may stem 
from the fact that pertussis is a disease for which epidemics are not infrequently reported 
2
• The period which was used to estimate the numbers of subjects available for study 
included one such epidemic year IJ. This epidemic bad ended by the time approval from 
the various ethics committees and granting agencies had been received and the project 
could be implemented. As a result, fewer children contracted the disease than had been 
anticipated, and therefore fewer children were available for enrollment in the study. 
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Another design-related reason for our failure to achieve the desired 
numbers of subjects was the reliance on other practitioners to make referrals of 
appropriate candidates for study entry. This recruitment strategy has been consistently 
inadequate to achieve recruitment goals in large multicentered adult trials of various 
medications and treatment options 90• As early as 1983, the Coronary Primary Prevention 
Trial was plagued by similar problems when only 25% of the required sample size had 
been enrolled by the midpoint of the recruitment period as a result of relying solely on 
physician referrals 92• In that study, the expansion of recruitment efforts to include 
workplace screening of potentially eligible adults, mass media campaigns, blood bank 
donor screenings, ·community screenings and mass mailings improved the accrual rate 
four-fold. Similarly, a study on diabetes care for older adults 93 reported that only 11% of 
418 enquiries from potential subjects were generated by physician referral, with only 6% 
of the 103 subjects entered in the trial deriving from these referrals. This contrasted with 
84% of enquiries and 87% of enrollments generated by referrals from combined 
community-directed recruitment efforts. Further, a study on the most effective strategy to 
use to recruit subjects for a study on astluna found that waiting for referrals from other 
practitioners resulted in recruitment of only 13% of the total subjects entered into the trial 
when compared with 87% recruited using the alternate methods of actively screening 
charts and telephoning potentially eligible candidateg94. These findings were again 
confirmed by those of the trial of hypertension prevention. The investigators in this 
group foWld that the combination of "referrals from medical and dental offices, friends, or 
other sources and attempts to recruit from lists of participants from previous research 
studies yielded only 4% of the randomized group." 9s 
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While these authors have emphasized the dangers of relying on other 
practitioners to provide referrals of subjects for entry into clinical trials, in defence of the 
strategy we employed~ the nature of pertussis infection and the disease it causes mean that 
options for recruitment in this situation were rather limited. This is particularly true in 
the setting of the Newfoundland health care system. In this system, pediatricians are not 
providers of primary health care and, therefore, are not usually the "front line'' members 
of the health care team. When studying a disease Like whooping cough, which presents 
acutely and which may masquerade as a number of other simpler problems, reliance on 
front line practitioners is necessary. Complicating matters further was the fact that, since 
recruiting problems had not been anticipated, there was no budget to allow for 
community advertising, the preparation of posters or the use of other mass media methods 
to inform the general public and general practitioners about the opportunity for study 
enrollment. Furthermore, given the current health care system, as outlined above, such 
advertising may have been seen as an attempt to lure patients and the economic benefits 
they bring, away from general practitioners. The professional ethics of such a strategy 
are, therefore, worthy of consideration. Hence, the potential backlash stemming from this 
situation may have precluded such a recruitment strategy, even if funding had been 
available. 
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Other problems with the study design which contributed to the lack of 
enrollment included the lack of adequate telephone follow-up for contacts. A maximum 
of three telephone calls were made. Where answering machines were present, messages 
were left but seldom returned. Extending the number of calls to nine and distributing 
them more evenly throughout the week may have resulted in improved recruitment rates. 
Koepsell and his colleagues at the University of Washington conducted a randomized 
trial of leaving messages on telephone answering machines in order to recruit controls for 
a study on Lou Gehrig's disease 96 • They used random-digit-dialling to find telephone 
numbers and called each. number up to nine times. These calls were distributed evenly 
between weekdays during the day, weekday evenings, and weekends. They were 
successful in reaching 62% of numbers tried wh.en no message was left, but reached 85% 
of numbers when a message was left. Our own lack of persistence in this area was 
primarily a reflection of the limited budget with which we were operating, rather than a 
true design flaw. 
Paradoxically. another of the design-related "flaws" which may have 
contributed to our low recruitment was the choice of a randomized placebo-controlled 
trial design. The use of a "medicinal placebo" may have enhanced recruitment by making 
it seem as though subjects were receiving "treatment" in both arms of the trial. 
Possibilities for such a study include a test of bronchodilators alone in comparison with 
broncbodilators and beclomethasone; or a comparison of an oral cough elixer, such as 
dextromethorphan, with inhaled steroids. Problems with such a design would include 
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difficulties in blinding and ethical issues related to the apparent deception of parents and 
children. 
The final design-related problem which may have resulted in fewer 
subjects available for enrollment into the trial was a failure to adequately inform the 
medical community of the trial and enlist their support before beginning the recruitment 
effort. Efforts were made to enlist the support of those physicians working at the 
pediatric centre. These included several letters to all medical staff, informal discussions 
with high profile medical staff members and a presentation at the annual research forum. 
However. general practitioners were not informed of the project until after the recruitment 
effort had actually begun. The reason for this was that it was felt that all patients with 
clinical pertussis would be referred to the tertiary centre for nasopharyngeal swabs and so 
would be identified in the laboratory screening efforts. Such proved not to be the case 
and may have resulted in a loss of potential subjects for the investigation. The 
importance of informing physicians early in a recruitment effort has been emphasized by 
Croft et al. in their report on recruitment strategies employed in the Bogalusa Heart 
Study, a study to determine risk factors for cardiac disease in children. These authors 
successfully recruited between 80 and 93% of the entire pediatric population of the area 
under study using a combination of techniques directed at the community. The very first 
of these techniques was "the establishment of supportive and cooperative communication 
with all local physicians." 97 These recommendations have subsequently been confirmed 
by Petrovitch et al.91 when reporting on their experience with screening and recruitment 
for the systolic hypertension and the elderly program. These authors listed the need to 
inform the medical and lay communities about a recruitment effort early in an 
investigation, as well as the need to inform local medical associations of ongoing 
recruitment efforts, as two of twelve specific suggestions for improving recruitment in 
future collaborative trials. 
Disease-related Problems 
90 
In addition to recruitment problems stemming from the study design, there 
were also problems related to the particular disease under study. Some of these have been 
alluded to earlier, including the epidemic nature of pertussis infection and the acuity of 
onset of the illness. Other problems relating to pertussis itself include the potential 
confusion of symptoms of pertussis infection with those of other diseases and the 
seasonal variation in pertussis incidence which required concentration of recruitment 
efforts over a relatively short period of time each year. The absence of a laboratory-based 
gold standard for diagnosis and the lack of a sensitive and specific clinical case definition 
were also problematic. 
In relation to the epidemic nature of pertussis, the problems this caused 
with the recruitment effort have been previously outlined. The absence of epidemic 
levels of pertussis infection during the years of the study meant that the numbers of 
infected children were significantly tower than in the previous year 13• 14• This decreased 
the pool of patients available and therefore, decreased the numbers of subjects recruited. 
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Such problems are likely to be observed in any study of an infectious disease which 
exhibits epidemic qualities. Compounding these difficulties is the fact that the acute 
onset of whooping cough results in difficulties with recruitment efforts aimed directly at 
subjects in the community. Instead, one must rely on primary health care providers to 
correctly identify the problem and refer the subject as has already been described. 
Problems such as these may be addressed in future studies by completing necessary 
planning and administrative work, such as securing ethics committees' approval in 
advance. This would mean that in the event of the appearance of epidemic rates of 
pertussis infection in the community, investigators could be ready to implement the 
recruitment phase of the trial. Such a project would best be undertaken by an established 
research group with adequate accessible funding to ensure that commencement of the 
project would not be hampered by the lack of readily available financial resources. 
Other problems relating to pertussis which magnified recruiting difficulties 
include the absence of a sensitive and specific case definition and the absence of an 
adequate laboratory-based gold standard for diagnosis. The case definition used in our 
study was purposely designed to be broad with the only requirement being that the subject 
have a clinical history compatible with Bordetella pertussis infection. This must have 
included a history of paroxysmal coughing which may or may not have occurred 
following a period of catarrhal symptoms. The coughing paroxysms may or may not have 
been followed by vomiting, apnea. cyanosis, or an audible whoop. A study by Patriarca 
et al. to examine the sensitivity and specificity of various clinical case definitions of 
92 
pertussis showed that the presence of a paroxysmal cough for at least 7 days was only 
54% sensitive and 77% specific when compared with culture results as the gold standard. 
This definition was not tested with serologic results as the gold standard 99• Halperin et 
al. 100 tested a clinical case definition of pertussis which required the presence: of cough 
for more than two weeks with vomiting, cyanosis, paroxysms or apnea. Using data 
provided, the calculated sensitivity is 71% and the specificity is 65%. The gold standard 
in this investigation was the presence of any positive laboratory test (culture. direct 
immunofluorescence, or serology) for recent pertussis infection. It is difficult to apply 
these results directly to our study because the case defmitions are different. Additionally, 
their literal interpretation is limited by the fact that the laboratory "gold-standards" 
employed to produce them are also flawed 101 , as discussed below. However, it is clear 
that the clinical diagnosis of whooping cough is imperfect. As is evident from our 
results, many subjects were excluded because they were not felt to meet the clinical case 
definition. It is quite possible that significant numbers of these subjects were actually 
~ted and that their exclusion resulted in a group of "false negatives" in the 
application of our case definition as a clinical test. If such is the case, it would clearly 
have negatively affected recruitment 
Unfortunately, the lack of sensitivity and specificity for the diagnosis of 
pertussis is not limited to clinical case definitions. Laboratory methods for disease 
identification are equally problematic. Halperin et al. compared the results of various 
serological tests, culture of nasopharyngeal aspirates and direct immunofluorescence 
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against a "gold standardn of a positive result in any of the tests to detennine the 
sensitivity and specificity of the various methods 100 • His group found that the sensitivity 
of nasopharyngeal culture was only 26%. This compared with a sensitivity of individual 
acute serological tests to two antigens (pertussis toxin and filamentous hemagglutinin) of 
31%. Specificity of both tests was 100%, reflecting the choice of the gold standard. 
While paired (acute and convalescent) serology enhanced detection of positive cases to 
88%, such an approach would not have been practical for our investigation because it 
required repeat testing three weeks after the initial serum sample. We needed to be able 
to randomize subjects from the time of our first contact with them. These findings 
indicate that while the use of laboratory tests can enhance the detection of pertussis 
infection, the practical utility of such information in a trial such as this one is limited. 
Consequently. our lack of serological testing is unlikely to have significantly influenced 
recruitment. Rather, recruitment was hampered by the lack of an adequate laboratory-
based diagnostic test. McNicol and her colleagues examined the utility of 
immunofluorescent microscopy in the diagnosis of pertussis infection102 • When 
compared with a ·~combination gold standard" of a positive pertussis culture or pertussis 
DNA as detected by polymerase chain reaction (PCR), the sensitivity of this method was 
only 32.3%, with a specificity of97.1%. Consequently, even this method, had it been 
available to us, is unlikely to have improved our identification of subjects significantly. 
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Population-related Problems 
One of the most difficult things about this investigation was that members 
of the population to be studied were children. While data on the recruitment of children 
into clinical trials are sparse, that which exists consistently points to the practical and 
ethical difficulties with the recruitment process which are encountered when the subject is 
a minor 10J..109• In such a case the person giving consent is, by necessity, a surrogate. 
lntroducing such a person into the decision process regarding study entry complicates that 
process considerably. 
ln discussing the difficulties associated with neonatal clinical trials, Mason 
uses words to the effect that "when their children are ill, parents may become anxious. 
They often experience feelings of powerlessness and may not understand medical 
arguments about the relative merits of one or another treatment made at such a time. 
Whether or not they agree to enter a trial, they may feel guilt as to whether or not they 
made the right decision"109• These sentiments are likewise implicit in an anonymous 
editorial published recently in The Lancet11J6. This editorial begins with a scenario meant 
to simulate a physician asking a mother to enter her newborn into a randomized. 
controlled trial and the mother subsequently discussing the matter with another person. 
The scenario is duplicated below: 
"Your baby is very ill and may die. There are two ways of 
treating his illness, and we would like to include him in a 
trial that we are doing to find which treatment is better . 
Please sign this consent form." 
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'~My baby's very ill, and the doctor doesn't know how to 
treat him! I don't want them to experiment on my baby, but 
if I say 'No' they might be cross and not look after him 
properly - even though they deny this. And why do they 
want me to sign something? What are they up to? I can't 
sort all this out at a time like this." 
The Lancet, April 1, 1995 
These are likely accurate reflections of the feelings of many parents when approached by 
investigators about entry of their child into a clinical trial. The impact of such feelings on 
recruitment rates for such investigations is unlikely to be positive. 
While our trial did not deal with children who were critically ill, even 
parents of children with lesser degrees of illness experience doubts about the entry of 
their children into clinical trials103· 107• Interestingly, they seem more willing to allow their 
children to participate in cohort or observational studies. Kramer and Shapiro report that 
in their study of adverse drug reactions in a general pediatric group practice, 96% of the 
parents of the 3316 children visiting the practice agreed to participate. In comparison, 
when 132 of those parents agreeing to participate in the observational study were asked to 
participate in a randomized controlled study on the use of acetaminophen in febrile 
children, 34% of them refused 103• This "experiment-related" anxiety has the potential to 
significantly limit enrollment of subjects from a pediatric population. 
In addition to experiment-related anxiety, there may also be a hesitancy to 
be randomised. This is perhaps particularly true for a placebo controlled trial where one 
of the treatments is very unlikely to improve the patients' medical condition (Hawthorne 
96 
and placebo effects excluded). Some parents may find this uncertainty unacceptable and 
refuse to enroll their child in a trial based on this feature alone 90• 103• 
In the case of our trial, the relatively heavy workload required by the 
parent may also have played a role in their refusal 105• While the use of a spacer device 
such as an aerochamberTM and mask is not painful for a chi I~ they often struggle and may 
cry during its use for the administration of inhaled medications. Our study protocol 
required the use of such a device for the administration of medication three times a day 
for 30 days. If parents had previous experience with these devices, they may have been 
hesitant to agree to such a treatment plan, either inside or outside the context of a clinical 
trial. lbis in tum may have adversely affected accrual rates for our study. 
The fact that the investigators conducting the trial were unfamiliar to most 
of the patients and families referred for possible entry into the trial may have had an 
effect on patient recruitment. lbis was suggested by the fact that several of the parents 
contacted by the research nurse deferred entry into the trial until they bad spoken with 
their general practitioner. Other investigators have also observed this phenomenon110• 
Postlethwaite and colleagues showed that patients often looked to their usual physicians 
for guidance when faced with decisions about embarking on a treatment plan for which 
there were no guaranteed benefits and for which the risks were non-neg1igible107• These 
authors reported the results of their efforts to recruit children into a clinical trial on the 
efficacy of growth hormone treatment in renal failure. They found that even when 
attempts were made to be completely neutral, some families requested advice and were 
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unable to make a decision without "help" from their attending physician. Therefore, the 
presence of a familiar physician, with whom a subject or his or her family has built a 
relationship, may be more likely to result in entry into the trial than refusaL 
Perhaps most surprising of the population-related reasons for subjects 
contacted to be excluded from the trial was that of already being on inhaled or systemic 
steroids. This may reflect clinicians' attempts to explain persistent cough in their 
pediatric patients on the basis of reactive airways disease. Presumably it did not reflect 
the presence of asthma in this group because all parents were asked if their children had 
asthma during the course of the screening interview. If the response was positive, they 
were asked to compare current symptoms with previous exacerbations of asthma. If 
symptoms were the same then the potential subject was excluded on the basis that he or 
she did not meet the clinical case definition and was~ therefore, ineligible for inclusion in 
the study. While some patients with reactive airways disease do go on to exhibit 
symptoms consistent with asthma, there is a general hesitancy to label patients with this 
diagnosis if it is their first episode of symptoms 111• Consequently, some practitioners 
prefer to use a therapeutic trial of anti-inflammatory medication usually combined with a 
bronchodilator in order to clarify the diagnosis112 • Unfortunately, in patients with 
pertussis, this strategy is open to bias in that the inhaled steroid could potentially have a 
positive effect on either condition. There was no way to monitor such an effect as these 
patients were excluded. 
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The problem of subjects having to be excluded based on their already 
being on inhaled steroids was paradoxically compounded by one of our strategies to 
improve recruitment. At the information dinner held in the community for local general 
and family practitioners one of the co-investigators spoke about pertussis in general and 
discussed the trial, requesting that the doctors refer patients for enrollment so that they 
could be randomized. Unfortunately, following this information session, some of the 
physicians began treating their patients with clinical pertussis with inhaled steroids 
without referring them for randomization. This may reflect the reluctance of general 
practitioners to relinquish care to the tertiary centre 90, or their discomfort with having 
their patients randomized to potentially receive a treatment which was unlikely to do 
good, namely placebo. Such a response is not uncommon. particularly in placebo-
controlled trials 10s. Perhaps physicians felt that, given the clear absence of benefit of 
placebo, and the anecdotal acclaim for the potential benefit of steroids, referral for entry 
into the trial would be unethical. More likely is that the extra time involved in referring 
patients was not felt to be cost-beneficial 90• They may have felt that, given that a study of 
inhaled steroids for use in pertussis was ongoing at the "tertiary centre," risks were likely 
to be low and benefits potentially significant. Consequently, patients were started on 
inhaled steroids without being entered in the trial. Unfortunately, the exact number of 
patients for whom this was the case was not recorded in the study, nor was data on their 
response to treatment. 
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Perhaps this problem could have been avoided by presenting information 
to physicians in a different manner, a maner which emphasized flaws in previous studies 
on steroids to a greater degree. This~ however, would be a delicate task. As pointed out 
in an article by Baum. "for a patient to be recrui~ the clinician has to be in perfect 
equipoise about either of the two treatments being evaluated" 113• To recruit under other 
circumstances Baum goes on to say, is ethically improper. While this view is extreme, 
there must be a balance between the potential benefits of the two medications being 
tested, or, in the case of placebo-controlled trials, between the benefits of the treatment 
and its risks. Consequently, emphasizing either risks or benefits to a greater or lesser 
degree may have bad the same effect. 
Review of Data Obtained 
Accepting that the number of subjects recruited for entry into the trial 
limits the generalizability of results, examination of findings is still valuable for 
hypothesis generation. Comparisons and contrasts with findings of other investigators 
further augments this utility. [n the sections that foUow, results obtained in the 
investigation will, therefore, be reviewed. 
Baseline Characteristics 
The ages of subjects enrolled in the trial ranged from 2 to 95 months. 
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While this differs from the ages of affected children reported in other trials10, these 
differences are likely primarily related to our inclusion criteria which required that 
children be less than 8 years old at entry. The older group was excluded because the 
disease tends to be more severe in the younger group 114• The inconvenience of 
medication administration was, therefore, not felt to be worthwhile in the older group of 
children. 
The number of days coughing before entry into the trial was similar 
between the beclomethasone and placebo groups, though those in the beclomethasone 
group had been coughing slightly longer than those randomized to the placebo group. 
The overall mean duration of coughing at entry into the trial was 14 days. This does not 
differ considerably from the duration of illness described by Zoumboulakis et al. 11 in 
their original study on the use of steroids in pertussis, though was slightly shorter than 
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that reported by Halperin et al 10• The latter difference is again attributable to the 
inclusion criterion which required subjects to have less than 21 days of coughing at entry 
into the trial. This period was chosen because of the proposed mechanism of the steroid 
effect. As discusse~ this is postulated to involve blocking of the infiltration of 
inflammatory cells into the airways with a resultant decrease in exfoliated cells and 
mucoid debris, and a subsequent reduction in cough. If such an effect were to have 
clinical value~ given the relatively slow onset of action of inhaled steroids, patients would 
have to be treated early in the course of their illness. 
The similarity between the duration of coughing at entry into our trial and 
that seen by Zoumboulakis et al. 11 is indicative of the ongoing difficulties experienced by 
physicians in diagnosing this illness. There continues to be a considerable lag time 
between the onset of symptoms and the clinical diagnosis of pertussis. Once diagnosed, 
however, patients with pertussis were identified by our project staff within a short period 
of time. This is supported by the relatively short mean duration of erythromycin therapy 
prior to study entry. Since erythromycin would not likely be the first-line therapy for 
most other bacterial respiratory infections, its use may indicate that the primary care 
physician was considering pertussis to be high on the differential diagnosis list. The short 
lag time between the time that erythromycin therapy was begun to the time subjects were 
entered therefore helps validate the identification method used for recruitment. 
Despite the reported increased prevalence of pertussis in girls 2, equal 
numbers of male and female subjects were recruited for this investigation. 
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The relatively high percentage of subjects reporting atopic disease 
represents a potential source of bias in the study. Children with respiratory illness in the 
first 2 years of life have an increased risk of asthma when atopic disease is present in 
themselves or a first degree relative 111 • Consequently, despite efforts to exclude children 
with symptoms of asthma from enrollment during the screening interview, several of 
those recruited may have been manifesting symptoms of asthma, rather than pertussis. 
However, 6 of the 8 subjects who reported atopic disease had positive pertussis swabs, 
indicating that they were truly infected. Hence, another explanation for the high 
proportion of atopic individuals in the sample population is that these individuals may 
have been predisposed to the development of pertussis. 
Attendance at daycare was similar in both groups and did not differentiate 
between subjects with positive and negative pertussis swabs. 
Baseline Symptoms 
The numbers of subjects exhibiting various pertussis-related symptoms 
seen in OW' study were similar, though not identical to those of other investigators. In OW' 
study, 72% of subjects exhibited vomiting as part of their symptomatology. This 
compares with 76% seen by Halperin et al. (1989) in their study ofNova Scotian children 
10
• In contrast, 72 % of our subjects exhibited whooping as compared with 58% of those 
in the study by Halperin et al. Likewise, only 17% of our subjects exhibited apnea, with a 
further 17% showing parentally-recognized cyanosis. This compares with 23% and 29% 
respectively in the Nova Scotia study. While these differences are small and likely a 
function of the low numbers of subjects recruited., given the younger age of subjects in 
our study, the lower incidence of apnea and cyanosis is somewhat surprising. 
LaboraJory Findings 
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Laboratory findings in this study were consistent with expected results in 
that chest X-ray and complete blood count (CBC) findings can be variable and of variable 
etiology 1 • Hence, the absence ofleucocytosis and lymphocytosis in those patients for 
whom CBC's were ordered does not preclude the diagnosis of pertussis. Chest X·rays 
were performed in a greater proportion of subjects in this investigation than in those 
reported by Gordon et al16• These researchers reviewed all subjects presenting with a 
diagnosis of pertussis to the Hospital for Sick Children in Toronto over an 11 year period. 
They found that 200/o of patients diagnosed with pertussis had a chest X-ray performed. 
This compares with almost twice that proportion in our study. The proportion of subjects 
with pneumonia was similar to that reported by Gordon et al. Fourteen per cent of 
subjects X-rayed in our study showed radiological evidence of pneumonia while 12% of 
patients in the group Gordon et al. studied exhibited such findings. The Toronto group 
did not report any X-rays as showing peribronchial thickening, which was the most 
common abnormal finding in X-rays on subjects in this investigatio~ being present in 
28% of those for whom X-rays were taken. 
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Follow-up Calls 
The purpose of these calls was to encourage ongoing participation, to 
assess progression and complications of the disease, and to assess potential side effects of 
medications. While parents of most subjects enrolled in the present study continued to 
participate in the trial throughout its duration, 5 parents opted to remove their children 
from the study prior to completion. This represents a retention rate of 78%, close to the 
800./o retention estimated in calculating the sample size. This observation suggests that the 
follow-up calls were at least partially helpful in encouraging parents to leave their 
children in the trial. A detailed discussion of the reasons for removal of subjects and 
subsequent handling of data follows later in this section and will not be reiterated. 
In assessing the progression and complications of disease, the follow-up 
calls did not provide any useful information beyond that provided by the cough diaries 
after the second call on day 16. Prior to this, a number of subjects were experiencing 
intercurrent illnesses which were treated in various ways by their family physicians. This 
information would have been lost if the first and second calls bad not been made. Had 
the number of subjects been larger, this information would have been important to have, 
particularly if the medications used were potential sources of bias. In the present 
investigation, such factors likely had little effect on the outcome of interest. 
The follow-up calls did show a cessation of whooping in all subjects by 
day 16 of the trial. Since the day that whooping started was not recorded, conclusions 
about the duration of this symptom in our population and comparisons of this data with 
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that of other investigators is not possible. However, results were consistent with expected 
findings in that whooping disappeared well before resolution of the cough 62. No 
difference in the relative times for disappearance of whoops and apneas between the two 
groups was detected. We did not quantify daily occurrence of whoops or apneas so 
differences in the actual times it took for these features to disappear are not reported. The 
number of subjects enrolled was far too small to detect any of the rare complications of 
whooping cough. 
One interesting feature was the development of otitis in one of our patients 
with culture-positive pertussis. While not commonly reported, this is not an unusual 
finding in pediatric patients with pertussis. The usual organism is Streptococcus 
pneumoniae1• This being the case, it is unusual that our patient failed to improve despite 
multiple anti-Streptococcal antibiotics. One explanation is that there was some persistent 
serous effusion following the acute infection which was interpreted by the family doctor 
as ongoing suppurative disease. 
The complications of study medications which were of interest to the 
investigators were the appearance of candida! mouth infection (thrush) and change in 
voice. [n addition, we sought to identify any unrecognized complications which might 
result from the use of inhaled beclomethasone in this therapeutic setting. No medication-
related complications were reported during the course of the follow-up calls. The single 
subject who experienced thrush was taking placebo. The other complications reported on 
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the first and second follow-up calls were not attributable to beclomethasone or placebo by 
any known mechanism of action and therefore~ were treated as coincidentaL 
Cough Duration 
The duration of coughing was the primary outcome variable for this 
investigation. Overall, subjects coughed for an average of38 days (median of 40 days) 
from the time of onset of their symptoms. This is slightly shorter than the duration of 
coughing reported by Bortolussi et al 62• They found a median total cough duration of 48 
days in immunized Canadian children. Reasons for this difference likely relate to 
differences in the populations studied. The inclusion/exclusion criteria for our study 
mandated the exclusion of those who had been coughing longer than 21 days. This may 
have resulted in a slightly lower mean (and median) duration of symptoms. Additionally, 
in our study, subjects were not followed after their 30 day treatment course. Fifty-five 
percent of our subjects continued to cough more than once per day at the end of this 
course. The duration that the cough persisted after the treatment ended is unknown. It is 
possible that if we had followed subjects to the disappearance of cough then similar 
results would have been obtained. The finding is potentially significant only in that it 
may mean that future researchers should follow children longer in order to document the 
clinical effect of a particular therapy. 
Following entry into the study and commencement of medicatio~ the 
mean duration of coughing for the placebo-treated group was 21.4 days while that in the 
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beclomethasone-treated group was 26.8 days. While these results did not achieve 
statistical significance, the fact that the duration of coughing in the placebo-treated group 
was shorter than that in the group receiving active treatment suggests that inhaled 
beclomethasone may make patients with whooping cough worse. 
Winrow recently reported a study in which pediatric pertussis patients 
were treated with inhaled, nebulized budesonide twice daily with resultant disappearance 
of apneas within 24 hours and improvement in "cough score" within 72 hours 10• Though 
not randomized or blinded, this paper suggested a role for inhaled steroids, particularly in 
the treatment of infants with pertussis. Other investigators as previously discussed, have 
found that oral or injected steroids may have a beneficial effect 7I.IG-I4. Our study 
contrasted these results in showing no benefit to inhaled steroids in the treatment of this 
condition. 
Possible reasons for the divergence in findings include the possibility that 
no treatment effect exists and that the study results accurately reflect the effects of inhaled 
steroids on the respiratory tracts of patients with whooping cough. Other explanations 
include the non-negligible possibility of a type II error due to differences in the groups of 
subjects at entry into the trial, problems with compliance, and the low numbers of 
subjects successfully recruited. Additionally, differences in dosage, route, method, and 
duration of medication administration in comparison with previous studies, as well as 
differences in the populations studied may have played a role. 
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While it seems most likely that no positive treatment effect exists, 
particularly in light of the trend towards better performance in the placebo group, there is 
a strong possibility that we have committed a Type II error. There are several potential 
explanations for why this may be so. First, more patients in the placebo group were 
culture-negative than in the beclomethasone group. The sensitivity of nasopharyngeal 
culture in pertussis is estimated to range from 26-80% when compared with a variety of 
other markers for infection, including serological tests and clinical criteria too. m . 
However, it is up to 100% specific100• Therefore, despite efforts to ensure that patients 
enrolled in the study actually had whooping cough, it is possible that some members of 
the placebo group who were culture-negative actually bad simple viral or post-viral 
coughs. If such were the case. then these patients would have been expected to improve 
more rapidly than those with true whooping cough. 
Despite the randomization process the beclomethasone-treated patients 
may have been sicker than the placebo-treated patients at entry into the trial. The 
beclomethasone patients had been coughing longer and were coughing more frequently 
than the placebo patients when the trial began. This being the case. they may have been 
expected to take longer to improve so that any observed effect would again be 
diminished. This latter possibility seems less likely in light of the similarity in the time it 
took subjects in each group to achieve a 25% decrease cough frequency. If the absence of 
a treatment effect on the duration of coughing in the beclomethasone-treated subjects had 
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been due to those patients being more ill, then the time to a 25% decrease in symptoms 
would be expected to be shorter for this group. 
Compliance may also have played a role. While there was little observed 
difference between the group compliance rates, 4 of the patients treated with 
beclomethasone failed to return their inhalers. Some investigators consider failure to 
return medication as an indicator of general non.compliance, even to the point of 
excluding such people from entry into a trial 103 • Such a process would not have been 
appropriate in this type oftrial 105 • Other investigators observed that an average of20-
25% of patients failed to return medication containers, though felt that this did not 
preclude them from analysis116• In the case of this trial, the lack of compliance with the 
study protocol may reflect a lack of compliance with medication administration, thereby 
making the actual compliance rate in the beclomethasone group significantly less than 
that calculated. If this is the case, then any observed treatment effect in this group would 
necessarily be blunted. 
Even the estimation of the required sample size may have been 
problematic in that assumptions made may have been flawed. The mean duration of 
coughing used to estimate A (the anticipated change in cough duration which would be 
clinically significant), as well as the standard deviation of this value were taken from the 
study by Zoumboulakis et aJ 11 • The mean duration of coughing in that study after entry 
into the trial was 19.3 days with a standard deviation of 6.5 days. For our trial, we found 
a mean duration of coughing in the placebo group of 21.4 days with a standard deviation 
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of 11.7 days. Using these numbers in the formula for sample size shows that even if the 
power was reduced to 800/o, 85 subjects would be required in each group in order to detect 
a 25% decrease in the duration of coughing. This number of subjects is too large to be 
realistically recruited from a smaller centre such as ours, and may have resulted in our 
trying to organize a multicentered trial, bad it been anticipated. 
The most problematic aspect of this study, is its lack of power. The 
difficulties experienced in recruiting resulted in low numbers in ,each treatment group, 
and subsequently, a decrease in power. The tendency towards an improvement in the 
placebo group prevents the use of a formal post hoc power calculation. Consequently, 
even though the study bas not shown a positive effect, the possibility that one exists can 
not yet be definitively ruled out. The tendency for more rapid improvement in the 
placebo group, however, makes this possibility more unlikely. Given results thus far, in 
order to show statistical significance in this trial, remaining subjects would have to 
demonstrate an average difference of 6.1 days less coughing in the beclomethasone group 
than in the placebo group. 
Differences in dosage, route, method and duration of medication 
administration may also explain the differences in our findings and those of other 
investigators. The only other trial of inhaled steroids"~ used budesonide rather than 
beclomethasone, in a dose of 500 meg twice daily for those less than 2 years old and 1 mg 
twice daily for those older tful:l 2 years. The author reports only administration by 
"standard nebulization technique .. without specifying whether this meant delivery by wet 
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nebulizAtion or delivery by metered dose inhaler. The duration of treatment is not 
specified but lasted ·~p to four weeks'" in some cases. The treatment was effective in the 
abolition of apneas within 24 hours but resulted in only improvement in ••scoring systems 
for cough .... coughing was not completely abolished." 10• While the dosages used by this 
author may be similar to ours when differences in potency are taken into accoun~ if the 
medication were administered by wet nebulization. then it is possible that variations in 
medication delivery to the tissues are responsible for the therapeutic effects observed. It 
may also have been the nebulization solution (for example, normal saline) that effected 
the improvement in symptoms through the improvement of pulmonary toilet. Further 
comparison of our findings to those of the Winrow study10 is difficult due to the general 
lack of information about the population studied and the interventions used. 
In considering results of other studies on the use of steroids in pertussis in 
relation to ours., a number of important differences are evident. For all of the other 
studies, while the duration of therapy was shorter than that in our study, the route of 
administration was oral or parenteral and the potency of the preparation used was much 
stronger117• Chandra et al. 12 used oral betamethasone in combination with 
chloramphenicol for an unspecified period of time to treat lndian children with pertussis, 
while Zoumboulak.is11, in the first placebo--controlled trial on steroids in pertussis, used 
intramuscular hydrocortisone daily for 7-8 days. Subsequent studies have employed oral 
prednisolone for 5 days 11, oral betamethasone three times daily for 10 day~ or 14 days71 
and oral dexamethasone daily for 4 days". All but oneu demonstrated a beneficial effect 
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in the groups treated with the steroid preparation. It may be that the short burst of strong 
anti-inflammatory activity obtained from oral or parenteral steroid preparations is more 
efficacious in preventing damage to the respiratory mucosa than inhaled preparations 
which have a relatively slower onset of action. It is equally possible that the inhaled 
agent acted as an irritant to the already inflamed airway so that any beneficial effects from 
the anti-inflammatory properties of the medication were negated. Such an effect would 
not have been evident with the oral or parenteral preparations. 
Disease Impact and Severity 
While again limited by the numbers of subjects enrolled. results of the 
disease impact questionnaire administered at the end of the study support other work by 
Mark and Granstrom in 1992... Their study showed that 54% of affected children had 
disturbed sleeping habits related to their illness. The same was true for 78% of parents. 
This group also reported that 55% of mothers and 34% of fathers had to stay home from 
work because of their child's illness. Our group had more extreme results with 94% of 
parents reporting illness-related sleep disturbance in both themselves and their children. 
In contrast to other author's findings, however, only 17% of parents reported having to 
take time off work because of their child's illness. This may be a reflection of the 
economic climate of the region. No statistical difference was seen in the reported impact 
in the placebo group as compared with the beclomethasone group. These findings 
indicate that despite virtually universal vaccination, pertussis continues to represent a 
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significant burden to the children and families afflicted with it. The need to find effective 
treatments for these children is even more apparent in the face of such evidence. 
Other Issues 
In addition to its direct findings, the study also highlighted a number of 
other points. The first is the difficulty in making an accurate clinical diagnosis of 
pertussis. While other investigators have relied on the use of the direct 
immunofluorescence 10• 100 or polymerase chain reaction (PCR)111, these tests were not 
routinely available at the Janeway laboratory and their cost was beyond the scope of our 
budget. Consequently, we relied on other physicians' clinical diagnosis with culture 
confirmation for case identification. As shown in table 4.1, after a review of symptoms 
by the investigators or the research nurse, 28.4% of patients referred for a pertussis swab 
did not have a clinical history consistent with classical pertussis infection. This has 
implications for future researchers in that before any treatments can be effectively tested, 
pertussis must be able to be diagnosed with certainty in the target population. At present, 
there appears to be no diagnostic tool available to practitioners which will allow them to 
make a definitive diagnosis of pertussis. Future work should, therefore, concentrate on 
finding a more reliable diagnostic test. If such a test is not found, then the inclusion of 
only culture-positive subjects in future therapeutic trials represents the most practical and 
scientifically valid alternative. 
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A surprising outcome from the study was the revelation of the number of 
patients with pertussis being treated in the community with oral or inhaled steroids. For 
the culture positive group, this was the most common reason for exclusion from the 
study. It is unknown whether this is a reflection of the background prevalence of asthma 
and reactive airways disease, on which a pertussis epidemic was transposed, or whether it 
represents general practitioners' misinterpretation of information sent out by the 
investigators about the study. If the latter is true, it underscores the necessity of 
providing full and accurate infonnation when recruiting patients into a clinical trial. It 
also emphasizes the potential dangers of relying on anecdotal evidence for clinical 
decision-making. In this case, patients were treated with a relatively iiiDocuous 
medication without definite ill effect. Applied to other situations, however, the practice 
could have more significant consequences. 
Fwure Directions 
Despite our efforts, the question of the utility of steroids, both inhaled and 
systemic, to treat patients with pertussis remains unanswered. Other studies will be 
required and will need to address some of the deficiencies in our project if they are to 
effectively answer the question. Based on the experience with this project, the following 
recommendations are made for future initiatives. 
Recruitment strategies should be established in advance with an adequate 
budget allotted to recruitment efforts. These efforts should include advance information 
liS 
to physicians and health professionals in the community, community advertising to alert 
the public about the project and frequent follow-up calls to ensure ongoing cooperation 
with the trial90• 97• [t would be helpful to have a staff member assigned to this job alone90• 
•os. During the recruitment effort, records should be kept of all referrals received~ 
contacts made and their disposal, including the reason for their exclusion if they are 
ineligible 90• 105• [f only culture positive children are included, the recruitment effort could 
be simplified significantly by focussing efforts on the microbiology laboratory. If 
telephone contact with potential participants is required then persistence and spreading 
calls evenly throughout the wee~ including some calls on weekends should be employed 
to maximize the yield 96• If smaller centres wish to initiate a project then they should 
consider involving other centres in the effort, as a multicentered trial would allow for 
greater numbers of subjects to be recruited 105• Alternately, preparing a protocol for 
implementation at the time of a pertussis epidemic would also be effective. 
An appropriate outcome measure for future trials would be the 
disappearance of cough and should be collected prospectively by direct questioning of 
parents. This could take the form of a telephone call every two days. Such an outcome 
would decrease the burden of the study for parents and might increase compliance. 
Consideration should be given to conducting another trial on the utility of 
inhaled corticosteroids in the treatment of pertussis, since our data were unable to 
definitively answer that question. Alternately, since the most dramatic results have been 
seen with systemic steroids and given that subjects in our trial who were treated with 
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steroids coughed longer than those treated with placebo, future studies on the efficacy of 
steroids in pertussis should consider focussing on the effect of a short burst of systemic 
steroid therapy. The side effects of such a treatment are likely to be minimal and the 
benefits may be significant. A multicentered trial would not be necessary if the 
investigation were conducted during an epidemic year and adequate recruitment were 
ensured. 
More work should be done in the area of pertussis diagnosis. The lack of a 
rapidly available diagnostic test is a major hlndrance to research on this not uncommon 
disease. In the interim, inclusion in therapeutic trials should be contingent on isolation of 
Bordetella pertussis from a culture of nasopharyngeal aspirate. The specificity of this test 
ensures that treatment effects seen will be applicable to the population with. clinical 
pertussis confirmed by any laboratory method. 
Summary of Findings 
In summary, this study has highlighted the difficulties in pertussis 
research, particularly from the point of view of case defmitions, diagnosis and defming 
and measuring an outcome variable. Additionally, it has re-emphasized the importance of 
an effective recruitment strategy in clinical trials research, and provided new insights into 
some of the difficulties encountered in implementing such a strategy in the pediatric 
population. In doing so it has allowed the development of a template for research into 
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treatments for pertussis which can be used to plan futme studies. thereby avoiding many 
of the problems encountered in this one. 
The results of the study, while limited in their power and generalizability 
by the low numbers of subjects enrolle~ suggest but do not prove that inhaled steroids 
are not effective in reducing the duration of paroxysmal coughing in pediatric patients 
with pertussis. The study also suggests that inhaled steroids do not result in more rapid 
improvement in other symptoms nor do they significantly lessen the impact of disease on 
child and parental sleep, or time lost from work. Future research on this question will be 
required before it can be definitively answered 
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Appendix A 
Centre-Specific Recruitment Letter 
Memo 
To: Janeway Pediatricians, Pediatric Residents, Casualty Officers. Marion Yetman 
(Infection Control Officer) 
From: Dr. Andrew Warren. Resident 
Dr. A.R. Cooper 
Re: Pertussis Study 
131 
After much preparation, we are finally ready to start recruiting patients for our 
study on the use of inhaled steroids to decrease coughing in pediatric patients with 
pertussis. The study is a randomized, double-blind clinical trial to examine the utility of 
inhaled steroids in decreasing the duration of coughing in patients with pertussis. Pa:.ients 
who are enroled will be randomly assigned to receive either inhaled steroids 
(beclomethasone 200mcg tid by aerochamber and mask) or placebo (demonstrator 
inhalant two puffs tid by aerochamber and mask) for one month (30 days). The parents 
will be asked to keep a diary of the child's coughing episodes. They will also be 
telephoned several times during the course of the study and asked to answer some 
questions about the child's progress. All medications are, of course, supplied free of 
charge. Both inpatients and outpatients are eligible for inclusion. 
We are requesting your help in recruiting patients to this study. The target number 
is 80, with accrual being accomplished over 2 years. Attached is a copy of the specific 
inclusion and exclusion criteria we are using. [f you see any patients with clinical or 
laboratory-diagnosed pertussis. please let us know. We have acquired the assistance of 
Marilyn Harvey, RN as a research nurse, which should make contact with the patients fast 
and efficient. 
Should you have a patient you wish to refer, please page Andrew Warren or call 
Marilyn at extension 567. Thanking you in advance for your anticipated cooperation. 
lnclusion I Exclusion Criteria 
[aclu.sioa Criteria: 
- Age 0-7 years. 
- Early disease { ie. less than 14 days of paroxysmal coughing). 
-Clinical history compatable with Bordetella pertussis mfection. 
{must include a history of paroxysmal coughing 
which may or may not occur following a period of 
cararrhal symptoms. The coughing paroxysms may or 
may not be followed by vomiting. apnea, cyanosis. or 
an audible whoop.) 
• A positive culture for Bordetella pertussis. 
E~~:dusion Criteria: 
- Refusal to participate. 
- Presently on steroids for othe!"' purposes 
(eg. asthma or rheumatic disease). 
- History of active or quiescent pulmonary tuberculosis. 
- History of untoward reaction to beclomethasone. 
yes no 
--- ---
yes _ _ no 
yes __ no _ _ 
yes no 
-- --
yes __ no 
yes no 
-- --
yes __ no 
If the answer to any of the conditions in the inclusion criteria is no. patient is ineligible. 
ffthe answer to any of the conditions in the exclusion cnteria is yes. patient is ineligible. 
Any question regarding patient eligibility should be discussed with investigators. 
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Appendix 8 
General Practitioner Recruitment Letter 
JanewaY'~ . 
January 18, 1995 
Dear Doctor: 
Janeway Place 
St. John's. Newfoundland 
Canada A.lA lR~ 34 
Telephone 709·7784222 
Facsimile 709-7784333 
This letter is to ask for your assistance in recruiting patients for a study which we 
have undertaken at the Janeway to test the efficacy of inhaled steroids in the treatment of 
pertussis. A number of articles have suggested that systemic steroids are useful in reducing the 
number and duration of coughing episodes in pediatric patients with this disease. Inhaled steroids, 
by virtue of their localized action and .low side effects profile might therefore be expected to be 
even better. 
Those that agree to participate wiD be gival either a steroid (beclometbasone) 
inhaler or a placebo inhaler which they will use t.i.d. for a total of one month. During that month 
they will be asked to record the total DUJDber of coughing episodes in a cough diary which wiD be 
given them. The end point of the study is the cessation of coughing as defined by less than or 
equal to one cougbiDg episode per day. AD patients wiD also be treated with erythromycin for 14 
days, as recommended by the Canadian Pediatric Society. 
Inclusion I exclusion criteria are listed on the back of this letter. If you see a 
patient with whooping cough, it would be much appreciated if you would send the child to the 
Janeway to bave a pertussis swab taken. Tbis wiD allow us to identify them (through the 
laboratory records) and offer them the opportunity ofparticpating in the study. Additionally, if 
you are contacted by any of your patients regarding this study, your positive support would also 
be appreciated. 
If you have further questions or concerns about this study, please contact one of 
the undersigned through the Janeway switchboard (n8-4222). Thanking you in advance for your 
anticipated support in this matter. 
Yours sincerely, 
AR Cooper, MD, FRCP(C) 
Pediatrician 
Andrew Warref\ MD 
Resident 
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Appendix C 
Cough Diary 
ID ## 
-~ 
--<./ ·---
PATIENT 
COUGH 
DIARY 
------
IF FOUND. PLEASE RETURN nus 
DOCUMENT TO: 
DR. ANDREW WARREN 
JANEWAY CHILD HEAL nt CENTRE 
PHONE: 778-4222 
-·-----<>-
Please record your child's coughing episodes in c.he boxes below. Use a stroke 10 record c:ach tplsodc:. For eumplc:. a child who has 12 wughing episodes 
per day would bave a box that looked like c.his: "fH.l tt1{ \ \ 
It is importllll to only record episodes you know about. If you forget to record on a panicular day, just wriae • forgm • and carry on with c.he next day . 
day l day ll day 21 
day2 day 12 day 22 
day3 day 13 day 23 
day4 day 14 day 24 
dayS day 15 day 25 
day6 day 16 day 26 
day7 day 17 day 27 
dayS day 18 day 28 
day9 day 19 day 29 
day 10 day 20 day 30 
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Appendix D 
Data Collection Forms 
Initial: 139 
------
DATA COLLECI10N FORM 
[)gnoRJPhics 
Source of referral: lab c:mc:rg pediatrician GP office __ 
Age: __ years __ moarbs 
Sex: __ male --female 
Dsycare~: __ yes __ oo 
V accina!ioos: __ up to dale 
__ partially vaccinated (dcfails) ----------
aavacciDatcd 
Chart#: 
------Study#: ____ _ 
Entry date: ____ _ 
Does your child have asthma? __ yes __ DO I Allergies __ yes __ DO I eczema __ yes __ DO 
Disease Cb.u!Ctcristics 
Date of onset of cooghiag ------
daylmootblycar 
Which of the foOowing symptoms docs be/she have currently (tick alllhat apply) 
coug!J.iq episodes 
vomiliog 
whoops 
stopping breathing (apoeas) 
tumiog bloc 
fever 
Which of tbe foUo"iog investigations bs your child bad completed? 
oasa1 swab 
Ireatmeot 
rcsulls: _____________ _ 
cb«:St X·ray 
~b: __________________ _ 
CBC 
results: WBC __ o/o lymphs __ ALC __ 
other tc:sts (details):-------------
How many days bas your child been receiviog Cf)1hromycin prior' to now (write 0 if oot oo Cf)'thromycio at presc:nO 
Has your child been oo another autibiotic besides erythromycin? __ ,·es __ oo 
If yes. wbat was/ is it aod what wasfas the dosc? __ ~---:--:----:------:--~-
ls your child currently on any other medication besides that mcotiooed above (foe c::umple puffers. etc.)? If yes. pl~ 
provide details ________________ _ 
c;omplicatioqs 
Since becoming ill. bas your child bad • piiCWilODia __ yes __ no 
-seizures __ yes_ no 
-aoy other complications whicb your doctor has attributed to whooping 
cough? (details) ____________ _ 
DATA COLLECI10N FORM 
FOLWW-UP 
Initial: 140 
Chart#: 
-----Study#: ____ _ 
Entry date: ____ _ 
Disease Characteristics 
Which of the foUowing symptoms does he/she have currently (tick all that apply) 
coughing episodes 
Complications 
vomiting 
whoops 
stopping breathing ( apneas) 
turning blue 
fever 
Since becoming ill, has your child had - pneumonia __ yes __ no 
-seizures yes __ no 
-any other complications which your doctor has attributed 
to whooping cough? 
(details) _____________ _ 
Is your child currently experiencing: 
thrush __ yes __ no 
change in voice __ yes __ no 
other symptoms not listed above (details): -------------
lnitiaJ: 141 
Chart#: 
-----Study#: ____ _ 
Entry date: ____ _ 
EXIT ADDENDUM 
Do you feel this illness has resulted in significance sleep disturbance for your child? _ yes _ no 
for you? yes __ no 
Has this illness required you or another caregiver to take time off work to look after your child? 
__ yes no 
If yes, How many days? ___ _ 
How would you rate the overall severity of your child's illness on the scale below? 
I 2 3 4 5 
mild (like a cold) moderate severe (life threatening) 
THANK YOU FOR YOUR COOPERATION IN mE STUDY!! 
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Appendix E 
Consent Form 
FACULTY OF MEDICINE 
MEMORIAL UNIVERSITY OF NEWFOUNDLAND 
ST. JOHN'S, NEWFOUNDLAND AlB 3V6 
CONSENT TO PARTICIPATE IN BIO-MEDICAL RESEARCH 
143 
TITLE: The Short-term Use of Inhaled Beclomethasone in Patients with Pertussis : A 
Randomized Clinical Trial 
INVESTIGATORS: Dr. Andrew Warren 
Dr. A.R. Cooper 
Dr. John Harnett 
Your child or ward has been asked to participate in a research study. Participation in this 
study is entirely voluntary. You may decide not to allow your child to participate or may 
withdraw from the study at any time without affecting your normal treatment. 
Confidentiality of information concerning participants will be maintained by the 
investigators. The investigator will be available during the study at all times should you have 
any problems or questions about the study. 
Purpose 
The purpose of this study is to determine whether the short-term use of inhaled 
beclomethasone to treat patients with pertussis (whooping cough) reduces the duration of 
coughing episodes significantly more than treating them with an inhaled non-toxic "fake-
drug" known as a "placebo." 
Procedures: 
[f you agree for your child/ward to participate in the study, you will be asked to answer some 
questions regarding your child's illness by one of the investigators or his delegate. The 
questionnaire is short and should take only about 5-l 0 minutes to complete. After 
completion of the questionnaire, your child/ward will be randomly assigned to receive one 
of two possible treatments, which he/she will receive three times per day for one month. You 
will be responsible for administering this treatment which consists of either I) inhaled 
beclomethasone (a steroid preparation usually used to treat patients with asthma) or 2) an 
inhaled placebo as described above. You will not know the treatment to which your child 
has been assigned, nor will the investigator until the study is over. Both treatments are safe. 
Over the following month you will be asked to record the number of coughing episodes per 
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day which your child experiences in a cough episode diary which you will be given. If your 
child goes to school, we will ask you to give the diary to his/her teacher to record daytime 
episodes. ln additio~ you will be contacted 8 times by telephone so we may check your 
child's progress. On the first 7 occasions you will be asked 6 short questions. These should 
take less than 5 minutes to answer. On the final occasion you will be asked several new 
questions relating to your estimation of the seriousness of your child's disease. This final 
questionnaire should take only 10 minutes to complete. Arrangements will also be made at 
that time for the return of puffers to the study coordinator. At the end of the study, cough 
diaries and answers from parents of children recieving both beclomethasone and placebo will 
be compared to see if there is a difference. 
In addition to the inhaled medication, all study participants will be treated with 
erythromycin (or alternative antibiotic if they are allergic) for 14 days as part of the standard 
treatment for pertussis. 
Possible risks. discomforts. or inconveniences 
Risks from either of these treatments are minimal. However, there is a slight 
risk that if your child is assigned to the steroid group, a slight facial rash, temporary changes 
in voice, mouth or throat irritation, or oral thrush (white mouth) may appear. This can be 
avoided by wiping the face and rinsing the mouth after each treatment. Since no one will 
know which children are getting the steroids until the end of the study, everyone will have 
their faces wiped and be asked to rinse their mouths after treatment. 
The only discomfort involved will be the use of the aerochamber and mask 
three times daily. This is not painful but younger children may struggle a little during 
administration. Most children tolerate it without much difficulty. 
Alternative procedures or treatment for those not entering the study 
If you choose not to participate in the study your child will be treated in 
exactly the way children with pertussis are usually treated. That is, with antibiotics (to 
prevent further spread of the organism) and supportive care. Other treatments are not 
standardized but some physicians may use inhaled steroids. Your refusal to participate in the 
research project will not affect your child's treatment in any way. 
Your signature on this fonn indicates that you have understood to your satisfaction the 
information regarding your participation in the research project and agree to the participation 
of your child/ward as a subject. In no way does this waive your legal rights nor release the 
investigators, sponsors, or involved institutions from their legal and professional 
responsibilities. 
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!, ___________ ___ __. the undersigne<L agree to the 
participation of _______________ , (my child/ ward) in 
the research study described. 
Any questions have been answered and I understand what is involved in the study. [realise 
that participation is voluntary and that there is no guarantee that I will benefit from my 
involvement. I acknowledge that a copy of this form has been given to me. 
Signature ofParent/Guardian _____________ .(Date) _____ _ 
Relationship to Participant Named Above: -----------
Witness Signature Date 
To be signed by investigator: 
To the best of my ability I have fully explained to the subject the nature of this research 
study. I have invited questions and provided answers. [ believe that the subject fully 
understands the implications and voluntary nature of the study. 
Signature of Investigator) (Date) 
Phone Number: 778-4222 (page) 
(Signature of Minor Participant) _ ____ _________ __ _ 
(Age ) _________ _ 
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Appendix F 
Letter Informing Attending Physicians of Patient Enrollment 
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Date: 
----------------------
Dear Dr.---------------------
Your patient,-------------------------. has entered a 
randomized, double blind, placebo-controlled clinical bial to test the efficacy of inhaled steroids in patients 
with clinically-diagnosed or laboratory-diagnosed whooping cough. 
The treatment being evaluated consists of two puffs of inhaled steroid (beclomethasone) or two 
puffs of inhaled placebo (propellant only) three times a day for 30 days. These are administered in a 
double-blind manner such that neither the investigator nor the patients/parents know which "drug" they are 
taking. Parents are asked to keep a diary of the child's coughing episodes, which will be used as the 
primary outcome measure. They are also being contacted at regular intervals to check on the progress of 
their child's coughing. 
Should you have any further ,questions about the study. or if. for emergency reasons. you nc!c!d to 
know which of the two drugs the patient is on, please contact Dr. A.R. Cooper or Dr. Andrew Warren 
through the Janeway switchboard (Ph. 778-4222). 
Your cooperation and support is greatly appreciated. 
Sincerely. 
Andrew Warren. MD 
A.R. Cooper. MD. FRCP(C) 
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AppendixG 
Human Investigations Committees Approval Letters 
Human Investigation Committee 
Office of Research and Graduate Studies IMedicinel 
Faculty of Medicine, The Health Sciences Centre 
February 2, 1995 
Reference #94. 155 
Dr. Andrew Warren 
Paediatric Resident 
Janeway Child Health Centre 
Dear Dr. Warren: 
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This will acknowledge receipt of your correspondence dated January 25, 1995, 
wherein you provide a revised consent form for the research study entitled "The Use 
of Inhaled Steroids to Treat Paediatric Patients with Pertussis". 
I have reviewed the information provided and now wish to advise that I am 
recommending full approval of the application. 
This decision will be ratified by the full Human Investigation Committee at a meeting 
scheduled for February 9th. 
We take this opportunity to wish you every success with your research study. 
Sincerely vo)J(i, 
w.B. nrungnusband, t-'tl.LY. 
Chairman 
Humal') Investigation ,eommittee 
HBY/jglo 
cc: Or. J . Harnett 
Dr. R. Cooper 
Dr. K.M.W . Keough, Vice-President (Research) 
Or. Wayne Andrews, Chairman, Et hics Committee, Janeway Hospital 
Dr. Kevin Hogan, Medical Director, Janeway Hospital 
St. John·s. NewfoundLtnd, C\NIU AlB 3V6 • Tel.: 17091 737.fi162 • Fu: 17091 737-6746 • Telex: 016-4101 
Dr. A. Warren 
c/o Janeway Child Health Centre 
Dear Dr. Warren: 
1994 12 L9 
.Janewav Place 
St. .John's. Newfoundland 
Canada AlA l R8 
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Telephone 709-778-4222 
Facsimile 709-778-4333 
Re: Short Term Use of Inhaled 8eclometbasooe to Reduce Duration of Paroxysmal 
Couphine in Pediatric Patients with Pertussis 
I am writing to advise you that your proposal was reviewed by the Janeway's Human 
Investigation Committee and that it is: 
~proved 
0 approved with the following questions, observations or limits (see attached) 
0 deferred pending receipt of additional information (see attached) 
D deferred pending your personal review of this proposal at the next Human 
Investigation Committee meeting. 
0 not approved. 
Should you have additional information or requests, please submit them to the committee 
(via Mrs. Haynes in Administration). 
mh 
cc Dr. A. R. Cooper 
Yours sincerely, 
Wayne L. Andrews, M.D., F.R.C .P.(C) 
Chairman 
Human Investigation Committee 
151 
Appendix H 
Proposed Budget 
PersoMel 
Research Nurse l (lh time) 
@ S 37397.08/ an. 
+ 20 % benefits 
Subtotal 
x 2 years 
Data Entry Clerk (I month) 
@ S 21964.24 I year 
+ 20 % benefits 
total 
Secretary I (1/10 time) 
@ $ 24254.37 I year 
~ 20 % benefits 
Subtotal 
x 2 years 
Accounting Clerk I (1/10 time) 
@ S 23183.57 / year 
+ 20 % benefits 
Subtotal 
x 2 yem 
Pharmacist II (1/10 time) 
@ S 41652.00 I year 
+ 20 % benefits 
Subtotal 
x 2 years 
Total Personnel Budget 
Expendibles 
Drugs and Drug Administration: 
Beclomethasone mdi's 
80 patients 
pediatric aerochambers and masks 
80 patients @ $25.50 
Total Drugs and Drug Administration 
Materials and Supplies: 
Printing of consent forms, data 
recording forms and parent 
questionnaires 
Budeet 152 
12465.69 
2493.14 
14958.83 
29917.66 
1830.35 
366.07 
2196.42 
2425.44 
485.09 
2910.53 
5821.06 
2318.36 
463.67 
2782.03 
5564.06 
4165.20 
833.04 
4998.24 
9996.48 
SJ-'95.68 
TO BE PROVIDED BY DRUG COMPANIES 
2040.00 
2040.00 
200.00 
Photocopying 
TOTAL MA TERlALS AND SUPPLIES 
TOTAL EXPENDIBLES 
Utility Services 
Telephone long distance 
@ 300.00 I year 
Postage@ 0.43/letter 
TOTAL UTILITY SERVICES 
Principal and Co-investigators to 
ttavel to international 
meeting to present data 
Publication 
5 pages@ 75.00 I page 
TOTAL OTHER 
TOTAL PROJECT BUDGET 
ACTUAL FUNDING RECEIVED 
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40.00 
~ 
2280.00 
600.00 
50.00 
650.00 
20QO.OO 
375.00 
SS8800.68 
Sl7 000.00 
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Appendix I 
Circuit Diagram of Cough-Recorder 
'o: Or Andrew Warren Janeway Child Health c.nFrom: JAMES TTTFORO 709-744·2365 1416196 14:15:36 Page 2 of 
COVGH COUNTER - Parts List 
a 
Ul 
U2 
U3 
U4 
Cl,C3 
r= 
C2. C4, CS 
Rl 
R2 
R3 
R4 
RS,R6 
R7, R12 
R8 
R9, Rl3 
RIO, Rl4 
Rll 
Jl, 12 
PI 
SWl 
Part NmniPcr 
uA324 
LWSS 
AQV201 
780S 
10 uF 
0.01 uF 
270 Otun 
10 Motun 
47 KOtun 
1 MOiun 
Description 
Quad Operational Amplifier 
Timer I Oscillator 
Solid State Relay 
+Sv Voltage Regulator 
Eleclrolytic 
100 Ohm All Resistors are rated 
6 .8 KOhm 5% and 118 watt 
27 Kotun 
l 0 KOhm Potentiometers 
l KOhm 
22 KOhm 
l/8 inch Phono jack 
l /8 inch Phono plug 
Momenwy Switch, Push Button Normally Open 
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Appendix J 
Pilot Project Protocol, Consent Formst 
and Human Investigation Committees Approval Letters 
The Use Of Sound-triggered Audio-tape Recording 158 
to Count Coughing Paroxysms in the Pertussis Population: 
A Pilot Study 
PROTOCOL 
l. PURPOSE: 
To generate statistics which can be used as a basis for designing a study of the 
effects of inhaled beclomethasone on the number of cough paroxysms per 24 hour period in 
the pediatric pertussis population. 
U. STUDY QUESTIONS: 
a) What is the inter-rater reliability of sound triggered audio-tape recording 
as a means of determining the number of coughing paroxysms per 24 hours in patients 
admitted with pertussis? 
b) What are the mean and standard deviation of the number of coughing 
paroxysms in children with pertussis? 
III. SUBJECT SELECTION: 
The number of subjects required is 6 (six). Subjects will be selected from 
patients admitted to the hospital witha a diagnosis of pertussis. Inclusion and exclusion 
criteria follow: 
Inclusion Criteria: 
-children with acute pertussis as defined by: 
a) A positive Bordetclla culcure. 
OR 
b) A compatible clinical history and a positive Bordetella culture in 
a close contact (where close is defined as a member of the same 
household or daycare, or someone with whom there has been close 
contact (in the same room) for greater than 3 hours per day within 14 
days prior to the onset of catarrhal symptoms). 
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-admitted to hospital 
Exclusion Criteria: 
-refusal to participate 
lV. METHODS 
After informed consent is obtained, subjects will be monitored using a sound-
triggered audio-tape recording machine designed by the Janeway's electrical engineer for this 
purpose. The apparatus consists of a nonnal audio-tape recorder fitted with a switch which 
is activated by sound. When the child coughs, the recording mechanism is activated. It 
remains activated for three minutes after the onset of coughing. If the paroxysm lasts longer 
than three minutes, the machine reactivates with little perceived break. This avoids under-
and over-counting of paroxysms. If the paroxysm is shorter than three minutes, the machine 
resets and waits for the next coughing episode. The only disadvantage of the apparatus is 
that it will also pick up extraneous noise in the child's room. 
Monitoring will involve simply placing the microphone of the audio-tape 
recorder near the child's head and recording his or her coughs. The audiotape will be 
manually changed periodically to avoid missed data. Subjects will be recorded for the entire 
duration of their admission. 
Once collected, audiotapes will be reviewed manually by both the primary 
investigator and the supervising staff and results will be compared for inter-rater reliabil ity. 
Providing this is acceptable, the mean and standard deviation of the number of coughing 
paroxysms per 24 hour period will be calculated. This data will then be used to design 
another study to look at the effect of inhaled bedomethasone on the number of coughing 
paroxysms per 24 hour period. 
V. ETHICS 
a) Informed Consent 
Informed consent will be obtained from parents or guardians of all study 
participants by the principal investigator or his delegate. A copy of the 
consent form is enclosed. 
b) Risk I Benefit Analysis 160 
There are few, if any, risks associated with this intervention. Potential 
benefits include the provision of statistics which will allow the design of a 
future study on the use of steroids in pertussis, as well as the provision of a 
reliable research tool for counting the number of paroxysms of coughing in 
this population and other similar ones. 
c) Confidentiality 
While the use of audio~tape recorders which may record conversation. as 
well as the intended coughing spells. presents some concerns about invasion 
of privacy, similar situations are not uncommon in the pertussis population. 
Patients admitted with pertussis are routinely placed in rooms that are 
monitored with intercoms. These devices also are capable of picking up 
conversation. 
To avoid any problems concerning this issue, parents will be told explicitly 
that conversation, as well as coughing, can be recorded by the machines and 
that any private conversations should be conducted outside the patient's room. 
Tapes will be marked only with the subject's code number, and the master 
code list will be kept under lock and key by the primary investigator. Tape 
reviewers will keep any information learned from reviewing the tapes in 
confidence. 
d) Cost to the System 
It is understood that patients will not be able to be admitted to the hospital 
solely for the purposes of this investigation. 
E7CUlll'Y CF MPDICINB 
ST. JaiN'S, ~' AIB 3V6 
CXHiENr '10 PARI.'ICIPME IN BICMEDICAL RE'.SE"AR:B 
Title: '!be Use of Samd triggered Audio-tape Ra:::onii.ng to Coont 
Ca.1gbiB;J Paroxysa& in Patients with Pertussis : A Pilot 
Stlxiy. 
Investigators: nr. Ardrew warren 
Dr. A.R. Cooper 
Your child has been selected to participate in a reseaz:ch study. 
Part.icipat:ial in this study is entirely voluntacy. Yen may decide 
not to allow your child to participate or may withdraw fran the 
stu:iy at any tine withatt affecting ytXIr childs l'XlDIBl treat:nent. 
Confidentiali.ty of infoz:mation concerning participants will be 
traintained by the investigator. '!he investigator will be available 
during the study at all times shou~d you have any problems or 
questia1s about the study. 
Put:pose 
'lb! purposes of this study are to test 1) the feasibility of using 
sound-triggered recardi.ng to count coughing episodes in patients 
with pertussis and 2) to determine the average and standard 
deviation of the nUJiber of coughs per 24 hours in this group of 
patients. 
Procedures 
If you agree to participate in the study, a special tape reco:r:der 
will be placed in your child's roan for the duration of his/her 
stay at the Janeway. Each tine the child coughs the tape-recorder 
will be activated and the cough will be recorded. 'lhe tapes will 
later be n!Vi.ewed by the investigator and the l1l.1DiJer of ca19hs per 
24 hcur period will be counted. Tapes will be marked and changed 
as necessary to ensure accurate date collecticn. 
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Risks, D.i.srxmfart arrl IB:x:nveni..erx 
The study will not cause any risk or discanfort for your child 
whatsoever. 'l1le fact that the tape-.r;econfer will also pick up ard 
record normal conversation may, however represent some 162 
i..nconYenierKJ. Ami oooversatial accidentally recotded will be kept 
in strict CCilfi.den:::e. 
Benefits 
While there are no inmediate benefits to subjects wb:> participate, 
the develq:uent of sound t.riggered reoonlinq as an effective ueans 
of research IIDnitorinq may allow the testing of medicines which 
could be of benefit to other children with pertussis (whopping 
cough) in the future. 
Alternative Procedures or Treatment for Those Not Entering the 
stu;iy 
If you choose not to participate in the study your child will be 
monitored and treated in exactly the same way children with 
pertussis are usually treated. This may or may not involve 
placement in a roan with an intercan to allow nursing staff to 
respond to coughing spells. Your refusal to pa.rti.cipate in the 
research project will oot affect yoor child's treat:mmt in any way. 
!'------------ 1 the mxJersi.gned, ag:l:ee to 
the part.icipation of. _____________ (U¥ child/ 
wani/relative) in the t:eseareh study de91 :r ibed. 
Any quest.ioos have been answered ani I understand what is involved 
in the study. I real ; ze that participatial is volunt:a.cy aiXi that 
there is no guarantee II¥ cbild/\18n:l/relative will benefit fran 
his/her .involvement. I ac:l<ni:Mledge that a copy of this fODil has 
been offered to me. 
Signature of Participant Date 
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To be signed by investigator 
To the best of my ahi 1 i ty I have fully explained to the subject's 
parent/guanii..an the natltte of this research study. I have .imri.ted 
questi.oos ard provided answers. I believe that the subject fully 
underst.ards the illplicati.als and voluntacy nature of the stu:iy. 
Signature of Investigator Date 
To locate the investigator yru oay page thralgh the hospital's 
switchboard ~tor. 
Signature of minor 
part..icipant 
Relationship to 
participant nailEd 
above 
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Human Investigation Committee 
Office of Resurch and GradlUte Studies IMedicinel 
Faculty of Medicine. The Health Sciences Centre 
21 February 1994 
aererence #94-11 
Dr. Andrew warren 
Resident 
Janeway Child Health Centre 
st. John's, Nfld 
Dear Dr. Warren: 
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At a meeting of the Human Investigation committee held on February 
10, 1994, your application entitled "A Pilot study on the use of 
sound-Triqqered Tape Recordinq to count couqh Parozyaas in the 
Pertussis Population" was considered. The Committee recommended 
approval of your application subject to a notice being posted on 
the door warning that conversations in the room might be recorded. 
As well, one specific modification was requested to the consent 
form as outlined on the attached. Please send a copy of the 
revised consent form to the HIC office. 
We take this opportunity to wish you every success with your 
research study. 
Sincerely yours, 
C. S. Mellor, MD, PhD, FRCP(C) 
Chairman 
Human Investigation Committee 
c.c. Dr. 
Dr. 
K. M. w. Keough, Vice-President (Research) 
Wayne Andrews, Chairperson, Ethics Committee, Janeway 
Dr. 
Dr. 
Hospital 
Kevin Hogan, Medical Director, 
A. R. Cooper, supervisor 
Janeway Hospital 
B Reunion 
~ Anniversary 
St. John's, Ncwioundland. Canada AlB 3V6 • Tel.: 17091 737-6762 • Fax: 17091 737-6746 • Tela: 016-4101 
166 
Reference 194-11 
The Committee requested the following modification to the consent fonn: 
Page 2 - Alternate Procedures, Delete line 3 "This may or may not involve placement in a room 
with an intercom to allow nursing staff to respond to coughing spells." 
T h t' [) r. C h a rl "·' . -l . 
Janeway Child Health Centre 
JANEWAY PLACE. ST JQ94r81N~FOUNDLAND CANADA A 1A ~R8 
J?r. A . . Warren ·and Dr. A. R. Cooper 
Dear Drs. Warren and Cooper: 
Re: Project 288-94 - A Pilot Study on the Use of Sound-Triffered Tape 
Recordine to Count Couehine Paroxysms in the Pertussis Population 
I am writing to advise you that your proposal was reviewed by the 
Janeway's Human lnvestigation Committee and that it is: 
Wapproved 
D 
D 
D 
D 
approved with the following questions, observations or limits (see 
attached) 
deferred pending receipt of additional information (see attached) 
deferred pending your personal review of this proposal at the next Human 
Investigation Committee meeting. 
not approved. 
Should you have additional information or requests, please submit them 
to the committee (via Mrs. Haynes in Administration). 
mh 
cc Dr. A. R. Cooper 
Yours sincerely, 
W,Ayne L. Andrews, M.D. , F.R.C.P.(C) 
Chairman 
Human Investigation Committee 
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